International Journal of Scientific & Engineering Research Volume 9, Issue 11, November-2018
ISSN 2229-5518

DNA Damage and Pulmonary Hypertension

Mr. Mubashar Tanvir, Dr. Saman Asghar Kashmiri, Dr. Maida Ulfat

Abstract— Aspiratory hypertension (PH) is characterized by a mean pneumonic blood vessel weight more than 25 mmHg very still and is analyzed by right heart catheterization. Among the diverse gatherings of PH, pneumonic blood vessel hypertension (PAH) is described by a dynamic hindrance of distal aspiratory corridors, identified with endothelial cell brokenness and vascular cell expansion, which prompts an expanded pneumonic vascular obstruction, right ventricular hypertrophy, and right heart disappointment. In spite of the fact that the essential trigger of PAH stays obscure, oxidative pressure and irritation have been appeared to assume a key job in the improvement and movement of vascular rebuilding. These elements are known to build DNA harm that may support the development of the proliferative and apoptosis-safe phenotype saw in PAH vascular cells. Large amounts of DNA harm were accounted for to happen in PAH lungs and renovated corridors and in addition in creature models of PH. Also, ongoing investigations have shown that hindered DNA-reaction components may prompt an expanded mutagen affectability in PAH patients. At long last, PAH was connected with diminished bosom malignancy 1 protein (BRCA1) and DNA topoisomerase 2-restricting protein 1 (TopBP1) articulation, both associated with keeping up genome honesty. This survey intends to give an outline of ongoing proof of DNA harm and DNA fix lack and their suggestion in PAH pathogenesis.

Index Terms— DNA damage, DNA-damage response, Inflammation, Oxidative stress, Pulmonary hypertension,

1. Introduction

Pneumonic hypertension (PH) is characterized by a mean aspiratory blood vessel weight more than 25 mmHg very still and is analyzed by right heart catheterization. Diverse gatherings are characterized dependent on PH etiology. In its most basic structures, PH can be because of ceaseless thromboembolic clumps (Gathering 4), continuous to left-sided heart or lung maladies (Gathering 2 and 3 separately), or because of essential blood vessel surrenders (Gathering 1, called pneumonic blood vessel hypertension [PAH]) [1, 2]. PAH is described by a dynamic deterrent of distal aspiratory supply routes and arrangement of plexiform injuries driving eventually to heart disappointment. The pathogenesis of PAH is unpredictable and includes pneumonic blood vessel endothelial cells (PAECs) brokenness, aspiratory blood vessel smooth muscle cells (PASMCs) expansion, apoptosis opposition, metabolic move (Warburg impact), hindered angiogenesis, phenotypic change, and ceaseless irritation [3,4,5,6,7]. At present, no fix exists for PAH and most treatments focusing on vasoconstriction, while offering symptomatic enhancement and deferring clinical declining, don't viably turn around this staggering ailment [2, 15]. For sure in spite of late upgrades in treatments, the assessed survival rate of patients influenced by PAH is 50%– 70% at 3 years [16]. Accordingly, a superior comprehension of PAH pathogenesis is obligatory to distinguish new restorative targets fit for interfering with the illness procedure.

Regardless of a poor learning of the occasions happening in beginning times of PAH, mounting proof demonstrates that oxidative pressure and aggravation essentially add to vascular rebuilding by advancing misrepresented contractility and multiplication of vascular cells [17, 18]. These variables are additionally known to support DNA harms. For sure, the DNA succession can be changed by blunder inclined DNA polymerases amid replication or by ecological factors, for example, mutagenic synthetic compounds, oxidative pressure, radiations, and interminable irritation. On the off chance that these harms are not accurately fixed, cells gather changes in their genome, which can prompt demise by apoptosis or now and again to an adjusted phenotype as saw in malignancy [19]. Expanded natural variables or potentially broken DNA-harm reaction systems may accordingly advance the rise of an apoptosis-safe and hyper-proliferative phenotype ensnared in vascular rebuilding [20]. The present audit gives a diagram of ongoing bits of knowledge demonstrating that DNA harm adds to PAH pathogenesis.

2. DNA Damage and Repair

DNA is chemically unstable in physiological conditions, like all biological macromolecules, and is vulnerable to hydrolysis, oxidation, and non-enzymatic methylation [21]. In addition to its intrinsic tendency to decompose, DNA lesions arise from endogenous and exogenous genotoxic agents. Endogenous genotoxic substances are produced by cellular metabolism, which is a source of reactive nitrogen and oxygen species (RNS and ROS), estrogen metabolites, and endogenous reactive chemicals such as aldehydes produced by lipid peroxidation [22] or alkylating molecules like S-adenosylmethionines involved in gene expression regulation through physiological DNA methylation [23,24]. Exogenous genotoxic agents refer to environmental events such as exposure to mutagenic chemicals or physical agents like UV or ionizing radiation (e.g., X-rays) [25, 26]. Resulting

DNA damages can be single-strand (SSBs) or double strand breaks (DSBs), basic site (also known as AP site (apurinic/apyrimidinic site)), modified bases, bulky adducts, interstrand/intrastrand crosslinks or insertion of intercalating agents [19,26,30,31,32,33].

DNA integrity is constantly threatened. SSBs, which are the most common type of DNA damage, occur more than 104 times per cell per day, only from endogenous DNA insults and spontaneous DNA decay [30, 34]. Taken together, the estimated rate of spontaneous DNA lesions is around 105 per cell per day [25]. The fate of cells against constant DNA damage lies on efficient repair mechanisms called DNA-damage response (DDR). DDR involves multiple pathways for rapid detection, signaling and repair of DNA lesions [35, 36, 37]

2.1. Single Strand Damage

SSBs are the most common DNA lesions. In this type of lesion only one of the two DNA strands has a defect with a missing or damaged nucleotide and altered 5′ and/or 3′ ends at the lesion site [30]. SSBs may results from attack of DNA bases and deoxyribose by ROS or other electrophilic molecules [38]. Three excision repair pathways exist to repair this type of alteration in DNA integrity, which are base excision repair (BER), nucleotide excision repair (NER) and mismatch repair (MMR).

BER is a pathway involved in resolving non-bulky DNA lesions by excising and replacing abnormal or damaged DNA bases (methylated, oxidized or reduced bases). During BER, the incorrect or damaged base is excised by DNA glycosylases then replaced by DNA polymerases and ligases [39, 40, 41, 42, and 43]. Poly (ADP-ribose) polymerase 1 (PARP1) can accelerate BER. PARP can bind on AP sites obtained following DNA glycosylases excision [30, 44, and 45]. When fixed, PARP1 synthesizes branched chains of poly (ADP) ribose (pADPr) polymers. PADPr allows the recruitment of X-ray repair cross-complementing protein 1 (XRCC1) scaffolding protein in complex with polynucleotide kinase (PNK), DNA polymerase β and DNA ligase III [46, 47, 48, 49]. PADPr polymers can give hundreds of AD PR monomers, which negatively charge the SSB site. Accumulation of negative charges opens the DNA strands, stabilizes them, and therefore facilitates BER repair. It also releases PARP1 from the AP site, which is then restored by Poly (ADP-ribose) glycohydrolase [30, 50, 51, 52].

Pathways involved in DNA lesions detection for the NER mechanism are mainly important for DNA damage induced by UV. They rely on damage sensor Xeroderma pigmentosum complementation group C and other proteins recruited at the lesion site, such as Cockayne syndrome protein [53, 54, 55]. Mutations in these NER proteins lead to severe diseases like xeroderma pigmentosum, Cockayne syndrome or trichothiodystrophy [56].

The MMR pathway recognizes base-base mismatches and insertion/deletion loops due to partner less nucleotides that appear during DNA replication [54, 57, 58]. Mutations on genes that code for proteins involved in MMR is linked to hereditary nonpolyposis colorectal cancer hereditary cancers [59, 63, 64].

2.2. Double Strand Damage

DSBs leave no integral strand that can be utilized as format amid fix. They speak to a more genuine danger for DNA honesty as they can prompt chromosome breaks and translocation. Three noteworthy pathways are involved in DSB fix: non-homologous end joining (NHEJ), homologous recombination (HR), and to a lesser degree micro homology-intervened end joining (MMEJ).

In the traditional NHEJ pathway, Ku70/86 heterodimer ties to the broken DNA strands and structures a complex with DNA-subordinate protein kinase. In the wake of selecting different proteins to the harmed site, a DNA ligase IV will seal the two closures of DNA strands [65, 66, 67, 68, 69, 70]. An option NHEJ pathway likewise happens in cells with lacking traditional NHEJ. The option NHEJ may likewise embroil PARP1, which is involved in SSB fix as depicted previously. PARP1 ties at the DSBs site and may enlist the Mre11-Rad50-Nbs1 complex and framework protein XRCC1/DNA ligase III complex to ligate DNA closes. In any case, the option NHEJ pathway prompts substantial erasure of DNA arrangements, modifications, and chromosomal translocation and additionally being associated with malignant growth cell genius survival phenotype [66,67,68,71,72,73,74,75,76,77,78,79].

HR is engaged with DSBs and interstrand crosslinks fix. It happens between late S stage and G2 period of the cell cycle and is a less blunder inclined fix pathway than NHEJ. The HR starts with a resection venture to create a 3′ single-stranded DNA end. The protein Rad51 communicates with Rad52, BRCA1, and BRCA2 (bosom disease 1 and 2) to make nucleoprotein fibers that drive strand intrusion to the homologous one from the accomplice chromatid in a relocation circle structure. The injury site is then fixed utilizing the homologous DNA layout [68,80,81,,86,87,88,89]. The decision among NHEJ and HR relies upon the cell cycle stage and also administrative factors, for example, p53-restricting protein 1 (53BP1) or BRCA1. Consequently it creates the impression that 53BP1 will support NHEJ while BRCA1 will advance HR [91, 92]. By and by, their suggestion isn't surely knew as BRCA1 may likewise assume a frill job

in NHEJ [93]. Both 53BP1 and BRCA1 insufficiencies have been connected to malignant growth improvement proposing that both HR and NHEJ are required for genome dependability [87, 94, 95, 96].

MMEJ depends on micro homologies of 2– 20 bp in both DNA strands. This system is as yet misty however among others, PARP1 may likewise assume a job in this sort of fix [77, 97, 98, and 99]. It gives the idea that DNA polymerase θ likewise advances MMEJ and represses homologous recombination [77,100]. MMEJ is a blunder inclined DNA fix pathway that favors oncogenic translocations and malignancy advancement [77, 98], and overexpression of DNA polymerase θ quality POLQ is related with poor survival [101,102].

3. DNA Damage in Pulmonary Arterial Hypertension

3.1. Evidences DNA Damage in PAH

First confirmations of physical hereditary transformations engaged with PAH pathogenesis were accounted for in 1998 as a monoclonal root of PAECs found in plexiform injuries in idiopathic and craving suppressant-related PAH [103,104]. In addition, microsatellite insecurities were seen in development and demise control qualities in PAECs from plexiform injuries [105]. Physical changes in PAECs are not particular to plexiform sores as serious hereditary anomalies were likewise seen in the greater part of PAH patients' PAECs and in explanted tissues [106]. Federici and partners [107] watched chromosomal variations from the norm in 30.2% of PAH-PAECs versus 5.3% in control PAECs. Strangely, DNA harm was not particular to the lung vasculature as it was likewise expanded in lymphoblastoid cell lines and fringe platelets from PAH patients when contrasted with control subjects. Expanded mutagen affectability to etoposide and bleomycin was likewise seen in fringe blood mononuclear cells from PAH patients and non PAH relatives contrasted with controls [107]. These perceptions bolster the theory of an inclined affectability to DNA harm prompted by the PAH condition that may go about as a trigger of the pathogenesis.

3.2. Irritation

Irritation is one of PAH trademarks and is emphatically connected with its pathogenesis. PAH can happen as an entanglement of different foundational fiery conditions, for example, lupus erythematosus, scleroderma, blended connective tissue malady, Hashimoto thyroiditis, Castleman sickness, Lyrics disorder, human immunodeficiency infection (HIV) contamination, and autoimmunity [108]. Sometimes, the utilization of calming treatments can enhance patients' conditions [109].

Notwithstanding the related ailments, irritation is available around renovated vessels in PAH patients' lungs. Undoubtedly, there is collection of perivascular incendiary cells, for example, B and T lymphocytes, pole and dendritic cells, and lymphoid follicles [6,113,114]. Irritation in PAH is additionally connected with expanded levels of star fiery cytokines, for example, IL1-β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and tumor corruption factor α (TNF-α) [120,121,122]. A few cytokines appear to be great pointers of PAH movement like the monocyte chemoattractant protein-1 (MCP-1), which is upregulated in beginning period of PAH [123] or like IL-6, IL-8, IL-10, and IL-12 that expansion with PAH seriousness and have all the earmarks of being markers of poor survival rate [121].

Preclinical information likewise show that irritation is unequivocally involved in the advancement of aspiratory vascular renovating. In reality, IL-6 organization or overexpression in rat is adequate to prompt pneumonic vascular rebuilding and to intensify incessant hypoxia-actuated PH [124,125,126]. On the other hand, IL-6 knockout mice are less powerless to create PH under hypoxia [127]. Aggravation supports master multiplication and expert survival phenotypes yet in addition DNA harm through expanded ROS/RNS levels delivered by vascular cells under fiery condition or greatly discharged by neutrophils and macrophages selected at irritation destinations. ROS/RNS harm DNA through DNA base oxidation and deamination, or through lipid peroxidation and base alkylation [128]. Among PAH-related cytokines, TNF-α is connected to expanded oxidative DNA harm in hepatocytes and myocytes, and irritation related malignancies by means of initiation of the translation factor NF-κB (atomic factor-κB), which advances cell survival [129,130,131,132]. ROS/RNS and DNA harm additionally advance straightforwardly or in a roundabout way DDR, which prompts irritation in an endless loop that is known to advance maturing and carcinogenesis [24,128,133]. For instance, DNA harm actuates IL-6 generation which advances survival and expansion however enactment of the JAK1-STAT3 flagging pathway in tumor cells [138,139,140].

Irritation in PAH may likewise be tweaked by modifications in the bone morphogenetic protein receptor type II (BMPR2) flagging pathway. BMPR2 loss-of-work changes increment powerlessness to PAH [141], and BMPR2 pathway modifications are enter highlights saw in PAH, adding to unusual provocative reaction through adjusted cytokines criticism direction like the one depicted in vivo and in vitro

for IL-6 in PASMCs [142,143]. For occurrences, decreased BMPR2 quality measurements (BMPR2+/−) in mice inspires a more grounded incendiary reaction after LPS (Lypopolysaccharide) presentation [144]. Comparable outcomes were seen in PAH-PASMCs harboring a BMPR2 change. The LPS provocative reaction in PASMCs disconnected from BMPR2+/− mice and from PAH patients conveying BMPR2 changes was related with a decreased articulation of extracellular superoxide dismutase 3 and expanded initiation of STAT3 [144]. Superoxide dismutase 3 is a cell reinforcement that counteracts oxidative harm and STAT3 was observed to be a noteworthy flagging segment downstream of diffusible variables dysregulated in PAH (like TNF, IL-6 and PDGF-β) and improving multiplication and protection from apoptosis [144,145,146]. In this investigation, endless introduction to LPS prompts PH improvement in of BMPR2+/− mice however not in controls, while PH and expanded aggravation were avoided by tempol treatment, a superoxide dismutase mimetic, affirming the endless loop of interminable irritation and oxidative worry in this PH demonstrate [144].

3.3. Oxidative Stress

Oxidative pressure is described by an expanded generation of oxidants species as well as diminished creation of cell reinforcements. It is related with expanded ROS and RNS and in addition diminished nitric oxide (NO) bioavaibility. Oxidative pressure appears to assume a critical job in PH [147,148,149,150] as it can support vessel thickening by expanding changing development factor-β1 (TGF-β1), vascular endothelial development factor (VEGF), fibroblast development factor-2 (FGF-2) [151], and platelet-determined development factor (PDGF) creation [152], and also by interceding endothelin-1-initiated PASMCs expansion [153]. ROS likewise upregulate hypoxia-inducible translation factors HIF-1α and HIF-2α articulation [154,155] additionally involved in PAH improvement [156,157]. Moreover, oxidative pressure can likewise advance vasoconstriction by means of expanded generation of endothelin-1 [158] and thromboxane A2 [159], diminished creation of prostacyclin [160,161], and expanded hypoxic cytosolic Ca2+ focus in PASMCs [162,163]. In concurrence with the pivotal job of oxidative worry in the pathogenesis of PAH [164,165,166,167,168], cancer prevention agent treatment was accounted for to have helpful impacts in creature models of the malady [169,170,171,172].

The oxidative pressure saw in PH is created by both incendiary and vascular cells. For sure, nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, which are vital wellsprings of ROS, are found in macrophages and polymorphonuclear and in addition in PAECs, PASMCs and fibroblasts [147,173,174,175]. In the lung vasculature, NADPH oxidases 1– 5 assume an essential job in expanding ROS age and advancing vascular brokenness in PH models. Under hypoxia, NADPH oxidases 2 has been connected to EC brokenness and vascular ROS creation [176] and its upregulation and actuation have been connected to neointima arrangement in creature models [177]. NADPH oxidases 4 upregulation in PAH and under hypoxia has been related to adventitial fibroblasts protection from apoptosis and adventitial fibroblasts and PASMC multiplication [173,178]. Strikingly, expanded level of TGF-β1, as saw in PAH serum, prompts NADPH oxidases 4 upregulation in PASMCs [179,180]. Vascular ROS can likewise be delivered in ECs by endothelial nitric oxide synthase under L-arginine or cofactor (BH4) exhaustion condition. In these cases, "uncoupled" endothelial nitric oxide produces ROS as opposed to NO [181]. L-Arginine inadequacy can be the consequence of diminished L-arginine generation, expanded creation/action of arginase or expanded simple rivalry with uneven dimethyl-l-arginine (ADMA). Hoisted plasma arginase movement was accounted for in sickle cell illness related PH [182] and expanded level of ADMA related to decrease ADMA catabolism by dimethylarginine dimethylaminohydrolase 2 was connected to PH [183,184,185]. At long last, ROS collection can be the consequence of disabled ROS rummaging framework. For sure, one of the significant cancer prevention agents ensnared, the superoxide dismutase 2, was found down-communicated in plexiform sores and inside the media and adventitia of redesigned little corridors from PAH patients [186]. In addition, as portrayed above, BMPR2 lack has additionally been related with lessened articulation of cancer prevention agent superoxide dismutase 3 in BMPR2+/− mice presented to LPS [144].

Expanded oxidative pressure prompts aggravation and cell wounds because of oxidation of proteins, lipids and DNA, which is seen in PAH patients [148,187,188,189,190,191]. The major oxidative DNA sore is created by oxidation of guanine into 8-hydroxydeoxy guanosine, which deliver changes after DNA can fix by G: C to T: A Trans versions [192,193,194]. It was as of late distributed that DNA harms saw in PAH-PAECs and PAH-lymphoblastoid cell lines were related with expanded levels of ROS [107].

3.4. Anorexigen Drugs and Selective Serotonin Reuptake Inhibitors

The solution of Aminorex, fenfluramines subordinates and Benfluorex utilized as craving suppressants was trailed by PAH pestilences [195,196,197]. Every one of these particles

share auxiliary and pharmaceutical likenesses with amphetamine subsidiaries which are additionally viewed as hazard factors for PAH [108,198,199,200,201]. Fenfluramines, amphetamines and subsidiaries had been accounted for to initiate foundational DNA harms through oxidative pressure [202,203,204,205,206,207,208,209,210,211]. Fenfluramine subordinates are additionally substrates for the serotonin transporter and strong serotonin take-up inhibitors [201,212]. All the more as of late, the utilization of particular serotonin-reuptake inhibitors (SSRIs) in late pregnancy was related with an expansion in the predominance of persevering aspiratory hypertension of the infant [213,214] and also clinical declining and expanded mortality in PAH patients [215]. Dhalla and partners [216] announced a positive relationship between SSRIs utilize and PAH. The serotonin and serotonin transporter (5-HTT) are involved in PAH pathogenesis by advancing PASMC expansion and vasoconstriction. 5-HTT articulation and action are discovered expanded in platelets and PH lungs. The utilization of 5-HTT inhibitor decreases the multiplication of PASMCs instigated by serum and serotonin [217] and its thump out in 5-HTT−/− mice was accounted for to weaken hypoxic PH [218]. Along these lines, it has been theorized that SSRIs may increment extracellular serotonin levels that influence PASMCs [212]. For sure PAH patients are more defenseless to serotonin-instigated PASMCs multiplication as 5-HTT articulation and action are discovered expanded in platelets and PAH lungs. This inclination can be clarified by long allelic variations of the 5-HTT quality advertiser that prompt expanded 5-HTT articulation in PASMCs. An investigation from Eddahibi and partner [217] revealed that 65% of PAH patients introduced homozygous long allelic variations contrasted with 27% of controls. Curiously, SSRIs are additionally known to have genotoxic impacts in patients and creature models [219,220,221,222,223,224]. Despite the fact that dysregulation of serotonin combination in PAH advancement is settled, SSRIs suggestion in early PAH pathogenesis is still discussed. In an ongoing report, Fox et al.reported that the two SSRIs and non-SSRIs stimulant medications are related with the equivalent expanded danger of PAH [225]. Also the nonattendance of connections be tween's the power of 5-HTT hindrance or the term of treatment and the danger of PAH improvement propose a non-causal affiliation. In this way the creators proposed that depressive side effects might be a hazard factor of PAH as adjusted serotonin flagging inclines to the two conditions [225]. Curiously, notwithstanding injurious impacts of dysregulated serotonin motioning on lung vasculature, it creates the impression that depressive issue additionally prompts expanded DNA harm and DDR lack [226,227].

Alkylating operators are antineoplastic atoms used to treat a few diseases. They respond with guanine base of DNA to make covalent bonds [228]. Contingent upon their structure, these operators can alter one nucleotide (monofunctional alkylating specialist) or two nucleotides (bifunctional alkylating specialists) which, for this situation, can make interstrand DNA crosslinks [229,230]. If not fixed, these DNA modifications prompt cell demise. In solid cells, BER, NER, and MMR pathways can proficiently evacuate these adjustments. Nonetheless, malignant growth cells will be intensely harmed due to their high proliferative phenotype and DDR lack (less blunder redressing limit). By the by, the nonspecific activity of alkylating operators can likewise incite changes in sound cells with quick division. Alkylating specialists are likewise known to make extreme wounds hepatic and pneumonic ECs [231,232]. It was as of late distributed that the utilization of bifunctional alkylating specialists utilized in chemotherapies were related with the improvement of pneumonic veno-occlusive illness (PVOD), a remarkable type of PAH both in human and creatures [233,234,235]. The utilization of mitomycin C, was related with high danger of butt-centric disease related PVOD (3.9/1000 every year) in examination with the uncommon frequency of PVOD in the all-inclusive community (<1/million every year) [234]. This symptom could be clarified by particular lethality of mitomycin C towards cells communicating abnormal state of the mitomycin C-actuating protein, NAD (P) H: quinone oxidoreductase. In fact, NAD (P) H: quinone oxidoreductase is overexpressed in different malignancies, yet additionally exceedingly communicated in typical aspiratory vascular endothelium [236]. The aspiratory vascular poisonous quality of cyclophosphamide could be clarified by the absence of detoxifying proteins, for example, aldehyde oxidase and aldehyde dehydrogenase [237] and by endothelial affectability to cyclophosphamide-actuated harm [238,239]. Notwithstanding DNA modifications, it was noticed that in vitro cyclophosphamide treatment exhausted glutathione in hepatic sinusoidal endothelial cells favoring oxidative pressure [240,241,242]. PVOD is additionally connected to word related exposures to natural solvents, for example, trichloroethylene likewise know to actuate DNA harms [243,244]. Strangely, monocrotaline, a plant poison used to actuate PH in rodents, winds up dynamic after it is processed in dehydromonocrotaline, a bifunctional alkylating specialist, that incites vascular harm [245,246,247]. Alkylating operators may thusly harm the vascular endothelium and breaking point its fix limit by repressing the expansion of outstanding PAECs. This may prompt a postponed aspiratory vascular damage, dynamic rebuilding, and PAH.

3.5. Alkylating Chemotherapies

4. DNA Repair Mechanisms in PAH Pathogenesis

DDR dysregulation has likewise been as of late recognized as a trigger associated with PAH pathogenesis. Meloche et al. [248] revealed that DNA harm in PAH was related with PARP1 overexpression in PASMCs because of an abatement in miR-223 articulation [249]. PARP1 keeps up cell survival in a setting of DNA harm however can likewise prompt expanded levels of IL-6, irritation and apoptosis opposition by means of miR-204/STAT3 intervened actuation of bromodomain-containing protein 4 (BRD4), atomic factor of enacted Immune system microorganisms (NFAT), and HIF-1α [248,250,251]. PARP1 restraint by ABT-888 has been appeared to switch PH in two creature models of the sickness (monocrotaline-and Sugen/hypoxia-instigated PH) [248]. Additionally, as beforehand depicted, PARP1 is embroiled in MMEJ and option NHEJ, which are known to initiate mistakes, DNA arrangements cancellations, revisions, and chromosomal translocation [98, 99,252,253,254,255]. Comparable perceptions were made with Pim1 and Surviving, two once-proteins overexpressed amid DDR enactment, related to expand DNA fix [256,257]. Their overexpression in PAH PASMC and monocrotaline rodent redesigned corridors was connected to expanded apoptosis opposition, expansion, and irritation which were weakened by their hindrance [258,259].

It has additionally been depicted that loss of BMPR2, can prompt weakened DNA harm fix [260]. In this article, Li and associates [260] detailed how downregulation of BMPR2 in PAH PAECs diminished BRCA1 articulation and expanded vulnerability to DNA harms. BRCA1 articulation was discovered diminished in endothelium from PAH redesigned vessels contrasted with control ones [260]. As beforehand portrayed, BRCA1 is embroiled in HR and NHEJ, yet its job stays indistinct. Entire exome sequencing has as of late prompted the disclosure of changes in another quality, topoisomerase DNA II restricting protein 1 (TopBP1), additionally associated with PAH defenselessness [261]. Adjustment of TopBP1 articulation was found in situ in PAECs from idiopathic PAH patients' lungs. TopBP1 is imperative in keeping up genome uprightness by averting DNA harm amid replication [262,263,264]. In this article [261], siRNA knockdown of TopBP1 brought about expanded DNA harm affectability and apoptosis in sound aspiratory microvascular ECs, though its reclamation utilizing plasmids in idiopathic PAH microvascular ECs diminished hydroxyurea-prompted DNA harm and enhanced cell survival. The connection between newfound PAH helplessness qualities and DDR reinforces the way that impeded DNA fix is engaged with PAH vulnerability. Curiously, PH can precipitously happen in creature models of debilitated DDR. It has been accounted for that Ku70−/− mice, that show debilitated NHEJ and genome insecurity, immediately create extreme aspiratory vessels redesigning and PAH [265]. Incessant restraint of p53, likewise engaged with NHEJ, with pifithrin-α was adequate to prompted PH in rodents [266]. P53 knockout additionally expands hypoxia-prompted PH in mice [267]. Finally, actuation of p53 pathway by Nutlin-3a treatment was accounted for to lessen PH in a creature demonstrate [268].

At long last, as abridged in an audit by Pouts et al. [269], DDR is intricate and its initiation can change small scale RNA pathways that are weakened in PAH [270]. Besides atomic DDR additionally influences, through the core to mitochondria flagging, the mitochondrial work and mitophagy [271].

5. DNA Harm: Past the Core

Mitochondrial brokenness has been connected to malignancy [272,273] and vascular and lung maladies including PAH [274,275,276,277,278]. ECs basically utilize glycolysis and don't depend on mitochondrial digestion. It has been recommended that endothelial mitochondria for the most part fill in as flagging organelles for hypoxic reaction, aggravation, apoptosis, and vasoconstriction [275,277,279,280,281]. PAH patients show dysmorphic, hyperpolarized mitochondria, mitochondrial splitting, mitochondria– Endoplasmic Reticulum Unit interruption, and metabolic change from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis (Warburg impact) [277,282,283,284,285,286]. Comparative perceptions of unusual mitochondria were made in Stoop Hooded rodents, a rodent strain with upset mitochondria-ROS-HIF-Kv pathway that precipitously creates PAH [282,287,288]. The utilization of dichloroacetate, a mitochondrial pyruvate dehydrogenase kinase inhibitor, enhances Grovel Hooded rodents PAH and also PH incited by constant hypoxia or monocrotaline [282,289,290] affirming the job of mitochondria brokenness in PH improvement. Strangely, it has been accounted for that modified BMPR2 articulation was likewise connected to PAECs mitochondrial brokenness [291,292]. Changed mitochondria is additionally ensnared in PASMCs apoptosis obstruction [284,285] and in right ventricle brokenness that happens in PAH and monocrotaline-initiated PH [293,294,295]. Curiously, mitochondria are more delicate to DNA harm, contrasted with atomic DNA since they need defensive histones and their DDR systems just depend on BER and MMEJ [296,297,298,299]. Additionally, it has been accounted for that mitochondrial DNA (mtDNA) harm fix in PAECs was to some degree slower contrasted with aspiratory venous

ECs and microvascular ECs [300] recommending that mtDNA harm may be embroiled in PAH. Besides, mtDNA harm has a potential job in sicknesses related with expanded hazard for PAH, for example, fundamental lupus erythematosus [301,302,303,304]. In an ongoing report, Fetterma and partners [304] discovered that expanded mtDNA harm in atherosclerosis and diabetes mellitus was related with expanded blood vessel benchmark beat sufficiency recommending a connection between mtDNA harm and unnecessary microvascular pulsatility. Sirtuin 3, a mitochondrial protein among others associated with mtDNA fix through 8-Oxoguanine glycosylase 1 [305] is downregulated in PAH patients and monocrotaline-incited PH rodent while Sirtuin 3 knockout mice unexpectedly create PAH [306]. In human glioblastoma cell lines, Sirtuin 3 consumption expanded illumination prompted oxidative harm to mtDNA [305]. DDR in mitochondria is less comprehended and contrasts from atomic DDR since comparable proteins may effectsly affect DNA honesty as saw with PARP1 [307,308]. While a job of mtDNA harm in the advancement and movement of PAH is hypothesized, assist examinations expecting to exhibit the nearness and impacts of mtDNA harm in PAH cells stay to be performed.

6. Conclusions

DNA harm is expanded in human PAH lungs, renovated courses, PASMCs and additionally PAECs. PBMCs additionally show expanded DNA harm, recommending that this marvel isn't confined to the aspiratory vasculature and that inherent mutagen affectability is available in these patients. Late investigations have discovered that PAH patients show impeded DNA harm fix related with TopBP1 and BMPR2-intervened BRCA1 down-articulations. Transformations in TopBP1 and BMPR2 qualities are related to PAH inclination. These DDR modifications prompt genome shakiness in the PAH condition that favors DNA harm. Undoubtedly the pathogenesis includes incessant aggravation and oxidative pressure that are firmly connected with expanded DNA harm. Furthermore, PAH has been connected to medications, for example, anorexigen and SSRIs that have genotoxic reactions. Besides, endothelial DNA harm because of presentation of alkylating operators, for example, cyclophosphamide or mytomycin C likewise supports PAH. As in malignant growth, expanded DNA harm as well as impeded DNA fix may advance the proliferative and apoptosis-safe phenotype that portrays PAH vascular cells. The ramifications of DNA harm was additionally revealed in PH creature models fortifying the perceptions made in human PAH. DDR systems are intricate and collaborate with cell pathways that advance straightforwardly or in a roundabout way expansion and apoptosis opposition embroiled in PAH improvement. As depicted beforehand for PARP1, DDR additionally advances aggravation and hence DNA harm in an endless loop. Every one of these confirmations abridged in the present survey (Figure 1) bolster the speculation that DNA harm affectability may go about as an early trigger of PAH. Both atomic and mitochondrial DDR are as yet not all around described and crosstalk between them or with other obsessive pathways may likewise be engaged with the pathogenesis. Additionally examines are then required to completely clarify how DNA harm and DDR add to PAH pathogenesis with the end goal to distinguish new helpful targets.



Figure 1

DNA damage and DNA-damage response mechanisms directly or indirectly involved in PAH pathogenesis via PAEC dysfunction and PASMC proliferation and apoptosis resistance (red). PAEC: pulmonary artery endothelial cell; PASMC: pulmonary artery smooth muscle cell; ↗: upregulation; ↘: downregulation.

Abbreviations

ADMA	asymmetric dimethyl-L-arginine
AP site	apurinic/apyrimidinic site; abasic site
BER	base excision repair
BRCA1	breast cancer 1
DDR	DNA-damage response
DSB	DNA double strand breaks
EC	endothelial cell
HR	homologous recombination
MMEJ	microhomology-mediated end joining
MMR	mismatch repair
NER	nucleotide excision repair
NHEJ	non-homologous end joining
PAEC	pulmonary artery endothelial cell
PAH	pulmonary arterial hypertension
PARP1	poly(ADP-ribose) polymerase 1
PASMC	pulmonary artery smooth muscle cell
PH	pulmonary hypertension
RNS	reactive nitrogen species
ROS	reactive oxygen species
SSB	DNA single-strand break

References

1. Hoeper M.M., Humbert M., Souza R., Idrees M., Kawut S.M., Sliwa-Hahnle K., Jing Z.-C., Gibbs J.S.R. A global view of pulmonary hypertension. Lancet Respir. Med. 2016 doi: 10.1016/S2213-2600(15)00543-3. [PubMed] [CrossRef]

2. Hoeper M.M., McLaughlin V.V., Dalaan A.M.A., Satoh T., Galiè N. Treatment of pulmonary hypertension. Lancet Respir. Med. 2016 doi: 10.1016/S2213-2600(15)00542-1. [PubMed] [CrossRef]

3. Humbert M., Montani D., Perros F., Dorfmüller P., Adnot S., Eddahibi S. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul. Pharmacol. 2008;49:113–118. doi: 10.1016/j.vph.2008.06.003. [PubMed] [CrossRef]

4. Tuder R.M., Archer S.L., Dorfmüller P., Erzurum S.C., Guignabert C., Michelakis E., Rabinovitch M., Schermuly R., Stenmark K.R., Morrell N.W. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J. Am. Coll. Cardiol. 2013;62:D4–D12. doi: 10.1016/j.jacc.2013.10.025.[PMC free article] [PubMed] [CrossRef]

5. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Investig. 2012;122:4306–4313. doi: 10.1172/JCI60658. [PMC free article] [PubMed] [CrossRef]

6. Cohen-Kaminsky S., Hautefort A., Price L., Humbert M., Perros F. Inflammation in pulmonary hypertension: What we know and what we could logically and safely target first. Drug Discov. Today. 2014;19:1251–1256. doi: 10.1016/j.drudis.2014.04.007. [PubMed] [CrossRef]

7. Ryan J., Dasgupta A., Huston J., Chen K.-H., Archer S.L. Mitochondrial dynamics in pulmonary arterial hypertension. J. Mol. Med. 2015;93:229–242. doi: 10.1007/s00109-015-1263-5. [PMC free article][PubMed] [CrossRef]

8. Potus F., Ruffenach G., Dahou A., Thebault C., Breuils-Bonnet S., Tremblay È., Nadeau V., Paradis R., Graydon C., Wong R., et al. Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation. 2015;132:932–943. doi: 10.1161/CIRCULATIONAHA.115.016382. [PubMed] [CrossRef]

9. Ranchoux B., Antigny F., Rucker-Martin C., Hautefort A., Péchoux C., Bogaard H.J., Dorfmüller P., Remy S., Lecerf F., Planté S., et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015;131:1006–1018. doi: 10.1161/CIRCULATIONAHA.114.008750. [PubMed] [CrossRef]

10. Potus F., Malenfant S., Graydon C., Mainguy V., Tremblay È., Breuils-Bonnet S., Ribeiro F., Porlier A., Maltais F., Bonnet S., et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2014;190:318–328. doi: 10.1164/rccm.201402-0383OC. [PubMed] [CrossRef]

11. Kherbeck N., Tamby M.C., Bussone G., Dib H., Perros F., Humbert M., Mouthon L. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin. Rev. Allergy Immunol. 2013;44:31–38. doi: 10.1007/s12016-011-8265-z. [PubMed] [CrossRef]

12. Malenfant S., Neyron A.-S., Paulin R., Potus F., Meloche J., Provencher S., Bonnet S. Signal transduction in the development of pulmonary arterial hypertension. Pulm. Circ. 2013;3:278–293. doi: 10.4103/2045-8932.114752. [PMC free article] [PubMed] [CrossRef]

13. Perros F., Humbert M., Cohen-Kaminsky S. Pulmonary arterial hypertension: A flavor of autoimmunity. Méd. Sci. 2013;29:607–616. [PubMed]

14. Montani D., Günther S., Dorfmüller P., Perros F., Girerd B., Garcia G., Jaïs X., Savale L., Artaud-Macari E., Price L.C., et al. Pulmonary arterial hypertension. Orphanet J. Rare Dis. 2013;8:97. doi: 10.1186/1750-1172-8-97. [PMC free article] [PubMed] [CrossRef]

15. Montani D., Chaumais M.-C., Guignabert C., Günther S., Girerd B., Jaïs X., Algalarrondo V., Price L.C., Savale L., Sitbon O., et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol. Ther. 2014;141:172–191. doi: 10.1016/j.pharmthera.2013.10.002. [PubMed] [CrossRef]

16. Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., Yaïci A., Weitzenblum E., Cordier J.-F., Chabot F., et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–163. doi: 10.1161/CIRCULATIONAHA.109.911818. [PubMed] [CrossRef]

17. Rabinovitch M., Guignabert C., Humbert M., Nicolls M.R. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 2014;115:165–175. doi: 10.1161/CIRCRESAHA.113.301141. [PMC free article] [PubMed] [CrossRef]

18. Intengan H.D., Schiffrin E.L. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581–587. doi: 10.1161/hy09t1.096249. [PubMed] [CrossRef]

19. Lodish H., Berk A., Zipursky S.L., Matsudaira P., Baltimore D., Darnell J. Molecular Cell Biology.W.H. Freeman; New York, NY, USA: 2000. DNA Damage and Repair and Their Role in Carcinogenesis.

20. Vaillancourt M., Ruffenach G., Meloche J., Bonnet S. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can. J. Cardiol. 2015;31:407–415. doi: 10.1016/j.cjca.2014.10.023.[PubMed] [CrossRef]

21. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 1993;362:709–715. doi: 10.1038/362709a0. [PubMed] [CrossRef]

22. Esterbauer H., Eckl P., Ortner A. Possible mutagens derived from lipids and lipid precursors. Mutat. Res. 1990;238:223–233. doi: 10.1016/0165-1110(90)90014-3. [PubMed] [CrossRef]

23. Holliday R., Ho T. Gene silencing and endogenous DNA methylation in mammalian cells. Mutat. Res. 1998;400:361–368. doi: 10.1016/S0027-5107(98)00034-7. [PubMed] [CrossRef]

24. De Bont R., van Larebeke N. Endogenous DNA damage in humans: A review of quantitative data. Mutagenesis. 2004;19:169–185. doi: 10.1093/mutage/geh025. [PubMed] [CrossRef]

25. Hoeijmakers J.H.J. DNA damage, aging, and cancer. N. Engl. J. Med. 2009;361:1475–1485. doi: 10.1056/NEJMra0804615. [PubMed] [CrossRef]

26. Ribezzo F., Shiloh Y., Schumacher B. Systemic DNA damage responses in aging and diseases. Semin. Cancer Biol. 2016 doi: 10.1016/j.semcancer.2015.12.005. [PMC free article] [PubMed] [CrossRef]

27. Helleday T., Eshtad S., Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 2014;15:585–598. doi: 10.1038/nrg3729. [PMC free article] [PubMed] [CrossRef]

28. Lindahl T., Nyberg B. Rate of depurination of native deoxyribonucleic acid. Biochemistry. 1972;11:3610–3618. doi: 10.1021/bi00769a018. [PubMed] [CrossRef]

29. Boiteux S., Guillet M. Abasic sites in DNA: Repair and biological consequences in Saccharomyces cerevisiae. DNA Repair. 2004;3:1–12. doi: 10.1016/j.dnarep.2003.10.002. [PubMed] [CrossRef]

30. Caldecott K.W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 2008;9:619–631.[PubMed]

31. Negritto C. Double-Strand Breaks in DNA Can Be Lethal to a Cell. How Do Cells Fix Them? [(accessed on 23 March 2016)]. Available online: http://www.nature.com/scitable/topicpage/repairing-double-strand-dna-breaks-14432332.

32. Stingele J., Jentsch S. DNA-protein crosslink repair. Nat. Rev. Mol. Cell Biol. 2015;16:455–460. doi: 10.1038/nrm4015. [PubMed] [CrossRef]

33. Noll D.M., Mason T.M., Miller P.S. Formation and repair of interstrand cross-links in DNA. Chem. Rev. 2006;106:277–301. doi: 10.1021/cr040478b. [PMC free article] [PubMed] [CrossRef]

34. Lenart P., Krejci L. DNA, the central molecule of aging. Mutat. Res. 2016;786:1–7. doi: 10.1016/j.mrfmmm.2016.01.007. [PubMed] [CrossRef]

35. Rouse J., Jackson S.P. Interfaces between the detection, signaling, and repair of DNA damage. Science. 2002;297:547–551. doi: 10.1126/science.1074740. [PubMed] [CrossRef]

36. Harrison J.C., Haber J.E. Surviving the breakup: The DNA damage checkpoint. Annu. Rev. Genet. 2006;40:209–235. doi: 10.1146/annurev.genet.40.051206.105231. [PubMed] [CrossRef]

37. Harper J.W., Elledge S.J. The DNA damage response: Ten years after. Mol. Cell. 2007;28:739–745. doi: 10.1016/j.molcel.2007.11.015. [PubMed] [CrossRef]

38. McKinnon P.J., Caldecott K.W. DNA strand break repair and human genetic disease. Annu. Rev. Genom. Hum. Genet. 2007;8:37–55. doi: 10.1146/annurev.genom.7.080505.115648. [PubMed] [CrossRef]

39. Wilson D.M., Barsky D. The major human abasic endonuclease: Formation, consequences and repair of abasic lesions in DNA. Mutat. Res. 2001;485:283–307. doi: 10.1016/S0921-8777(01)00063-5. [PubMed][CrossRef]

40. Demple B., Sung J.-S. Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair. 2005;4:1442–1449. doi: 10.1016/j.dnarep.2005.09.004. [PubMed] [CrossRef]

41. Izumi T., Wiederhold L.R., Roy G., Roy R., Jaiswal A., Bhakat K.K., Mitra S., Hazra T.K. Mammalian DNA base excision repair proteins: Their interactions and role in repair of oxidative DNA damage. Toxicology. 2003;193:43–65. doi: 10.1016/S0300-483X(03)00289-0. [PubMed] [CrossRef]

42. Dianov G.L., Sleeth K.M., Dianova I.I., Allinson S.L. Repair of abasic sites in DNA. Mutat. Res. 2003;531:157–163. doi: 10.1016/j.mrfmmm.2003.09.003. [PubMed] [CrossRef]

43. Kim Y.-J., Wilson D.M. Overview of base excision repair biochemistry. Curr. Mol. Pharmacol. 2012;5:3–13. doi: 10.2174/1874467211205010003. [PMC free article] [PubMed] [CrossRef]

44. Ménissier-de Murcia J., Molinete M., Gradwohl G., Simonin F., de Murcia G. Zinc-binding domain of poly(ADP-ribose)polymerase participates in the recognition of single strand breaks on DNA. J. Mol. Biol. 1989;210:229–233. doi: 10.1016/0022-2836(89)90302-1. [PubMed] [CrossRef]

45. Khodyreva S.N., Prasad R., Ilina E.S., Sukhanova M.V., Kutuzov M.M., Liu Y., Hou E.W., Wilson S.H., Lavrik O.I. Apurinic/apyrimidinic (AP) site recognition by the 5′-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1) Proc. Natl. Acad. Sci. USA. 2010;107:22090–22095. doi: 10.1073/pnas.1009182107. [PMC free article] [PubMed] [CrossRef]

46. Fisher A.E.O., Hochegger H., Takeda S., Caldecott K.W. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol. Cell. Biol. 2007;27:5597–5605. doi: 10.1128/MCB.02248-06. [PMC free article] [PubMed] [CrossRef]

47. Dianova I.I., Sleeth K.M., Allinson S.L., Parsons J.L., Breslin C., Caldecott K.W., Dianov G.L. XRCC1-DNA polymerase beta interaction is required for efficient base excision repair. Nucleic Acids Res. 2004;32:2550–2555. doi: 10.1093/nar/gkh567. [PMC free article] [PubMed] [CrossRef]

48. Caldecott K.W., Aoufouchi S., Johnson P., Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular "nick-sensor" *in vitro*. Nucleic Acids Res. 1996;24:4387–4394. doi: 10.1093/nar/24.22.4387.[PMC free article] [PubMed] [CrossRef]

49. Masson M., Niedergang C., Schreiber V., Muller S., Menissier-de Murcia J., de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol. 1998;18:3563–3571. doi: 10.1128/MCB.18.6.3563. [PMC free article][PubMed] [CrossRef]

50. Beneke S. Regulation of chromatin structure by poly(ADP-ribosyl)ation. Front. Genet. 2012;3:169. doi: 10.3389/fgene.2012.00169. [PMC free article] [PubMed] [CrossRef]

51. Rouleau M., Patel A., Hendzel M.J., Kaufmann S.H., Poirier G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer. 2010;10:293–301. doi: 10.1038/nrc2812. [PMC free article] [PubMed][CrossRef]

52. Schreiber V., Dantzer F., Ame J.-C., de Murcia G. Poly(ADP-ribose): Novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006;7:517–528. doi: 10.1038/nrm1963. [PubMed] [CrossRef]

53. Marteijn J.A., Lans H., Vermeulen W., Hoeijmakers J.H.J. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell Biol. 2014;15:465–481. doi: 10.1038/nrm3822.[PubMed] [CrossRef]

54. Torgovnick A., Schumacher B. DNA repair mechanisms in cancer development and therapy. Front. Genet. 2015;6:157. doi: 10.3389/fgene.2015.00157. [PMC free article] [PubMed] [CrossRef]

55. Hanawalt P.C., Spivak G. Transcription-coupled DNA repair: Two decades of progress and surprises. Nat. Rev. Mol. Cell Biol. 2008;9:958–970. doi: 10.1038/nrm2549. [PubMed] [CrossRef]

56. Knoch J., Kamenisch Y., Kubisch C., Berneburg M. Rare hereditary diseases with defects in DNA-repair. Eur. J. Dermatol. 2012;22:443–455. [PubMed]

57. Guillotin D., Martin S.A. Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp. Cell Res. 2014;329:110–115. doi: 10.1016/j.yexcr.2014.07.004. [PubMed] [CrossRef]

58. Li G.-M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18:85–98. doi: 10.1038/cr.2007.115. [PubMed] [CrossRef]

59. Modrich P., Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem. 1996;65:101–133. doi: 10.1146/annurev.bi.65.070196.000533. [PubMed][CrossRef]

60. Kunkel T.A., Erie D.A. DNA mismatch repair. Annu. Rev. Biochem. 2005;74:681–710. doi: 10.1146/annurev.biochem.74.082803.133243. [PubMed] [CrossRef]

61. Jiricny J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006;7:335–346. doi: 10.1038/nrm1907. [PubMed] [CrossRef]

62. Iyama T., Wilson D.M. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair. 2013;12:620–636. doi: 10.1016/j.dnarep.2013.04.015. [PMC free article] [PubMed] [CrossRef]

63. Arnheim N., Shibata D. DNA mismatch repair in mammals: Role in disease and meiosis. Curr. Opin. Genet. Dev. 1997;7:364–370. doi: 10.1016/S0959-437X(97)80150-5. [PubMed] [CrossRef]

64. Peltomäki P. DNA mismatch repair and cancer. Mutat. Res. 2001;488:77–85. doi: 10.1016/S1383-5742(00)00058-2. [PubMed] [CrossRef]

65. Ding Q., Reddy Y.V.R., Wang W., Woods T., Douglas P., Ramsden D.A., Lees-Miller S.P., Meek K. Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair. Mol. Cell. Biol. 2003;23:5836–5848. doi: 10.1128/MCB.23.16.5836-5848.2003. [PMC free article] [PubMed] [CrossRef]

66. Helleday T., Lo J., van Gent D.C., Engelward B.P. DNA double-strand break repair: From mechanistic understanding to cancer treatment. DNA Repair. 2007;6:923–935. doi: 10.1016/j.dnarep.2007.02.006.[PubMed] [CrossRef]

67. Deriano L., Roth D.B. Modernizing the nonhomologous end-joining repertoire: Alternative and classical NHEJ share the stage. Annu. Rev. Genet. 2013;47:433–455. doi: 10.1146/annurev-genet-110711-155540. [PubMed] [CrossRef]

68. Nicolai S., Rossi A., di Daniele N., Melino G., Annicchiarico-Petruzzelli M., Raschellà G. DNA repair and aging: The impact of the p53 family. Aging. 2015;7:1050–1065. doi: 10.18632/aging.100858.[PMC free article] [PubMed] [CrossRef]

69. Ahnesorg P., Smith P., Jackson S.P. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell. 2006;124:301–313. doi: 10.1016/j.cell.2005.12.031. [PubMed][CrossRef]

70. Roy S., de Melo A.J., Xu Y., Tadi S.K., Négrel A., Hendrickson E., Modesti M., Meek K. XRCC4/XLF Interaction is variably required for DNA repair and is not required for ligase IV stimulation. Mol. Cell. Biol. 2015;35:3017–3028. doi: 10.1128/MCB.01503-14. [PMC free article] [PubMed] [CrossRef]

71. Della-Maria J., Zhou Y., Tsai M.-S., Kuhnlein J., Carney J.P., Paull T.T., Tomkinson A.E. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J. Biol. Chem. 2011;286:33845–33853. doi: 10.1074/jbc.M111.274159. [PMC free article] [PubMed] [CrossRef]

72. Boboila C., Alt F.W., Schwer B. Classical and alternative end-joining pathways for repair of lymphocyte-specific and general DNA double-strand breaks. Adv. Immunol. 2012;116:1–49. [PubMed]

73. Metzger M.J., Stoddard B.L., Monnat R.J. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks. DNA Repair. 2013;12:529–534. doi: 10.1016/j.dnarep.2013.04.004. [PMC free article] [PubMed] [CrossRef]

74. Bunting S.F., Nussenzweig A. End-joining, translocations and cancer. Nat. Rev. Cancer. 2013;13:443–454. doi: 10.1038/nrc3537. [PMC free article] [PubMed] [CrossRef]

75. Audebert M., Salles B., Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 2004;279:55117–55126. doi: 10.1074/jbc.M404524200. [PubMed] [CrossRef]

76. Cuneo M.J., Gabel S.A., Krahn J.M., Ricker M.A., London R.E. The structural basis for partitioning of the XRCC1/DNA ligase III-α BRCT-mediated dimer complexes. Nucleic Acids Res. 2011;39:7816–7827. doi: 10.1093/nar/gkr419. [PMC free article] [PubMed] [CrossRef]

77. Sfeir A., Symington L.S. Microhomology-mediated end joining: A back-up survival mechanism or dedicated pathway? Trends Biochem. Sci. 2015;40:701–714. doi: 10.1016/j.tibs.2015.08.006.[PMC free article] [PubMed] [CrossRef]

78. Czornak K., Chughtai S., Chrzanowska K.H. Mystery of DNA repair: The role of the MRN complex and ATM kinase in DNA damage repair. J. Appl. Genet. 2008;49:383–396. doi: 10.1007/BF03195638.[PubMed] [CrossRef]

79. Lamarche B.J., Orazio N.I., Weitzman M.D. The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett. 2010;584:3682–3695. doi: 10.1016/j.febslet.2010.07.029.[PMC free article] [PubMed] [CrossRef]

80. Aravind L., Makarova K.S., Koonin E.V. SURVEY AND SUMMARY: Holliday junction resolvases and related nucleases: Identification of new families, phyletic distribution and evolutionary trajectories. Nucleic Acids Res. 2000;28:3417–3432. doi: 10.1093/nar/28.18.3417. [PMC free article] [PubMed][CrossRef]

81. Wyatt H.D.M., West S.C. Holliday junction resolvases. Cold Spring Harb. Perspect. Biol. 2014;6:a023192. doi: 10.1101/cshperspect.a023192. [PMC free article] [PubMed] [CrossRef]

82. Ip S.C.Y., Rass U., Blanco M.G., Flynn H.R., Skehel J.M., West S.C. Identification of Holliday junction resolvases from humans and yeast. Nature. 2008;456:357–361. doi: 10.1038/nature07470.[PubMed] [CrossRef]

83. Bizard A.H., Hickson I.D. The dissolution of double Holliday junctions. Cold Spring Harb. Perspect. Biol. 2014;6:990 doi: 10.1101/cshperspect.a016477. [PMC free article] [PubMed] [CrossRef]

84. Swuec P., Costa A. Molecular mechanism of double Holliday junction dissolution. Cell Biosci. 2014;4:36. doi: 10.1186/2045-3701-4-36. [PMC free article] [PubMed] [CrossRef]

85. Bocquet N., Bizard A.H., Abdulrahman W., Larsen N.B., Faty M., Cavadini S., Bunker R.D., Kowalczykowski S.C., Cejka P., Hickson I.D., et al. Structural and mechanistic insight into Holliday-junction dissolution by topoisomerase IIIα and RMI1. Nat. Struct. Mol. Biol. 2014;21:261–268. doi: 10.1038/nsmb.2775. [PMC free article] [PubMed] [CrossRef]

86. San Filippo J., Sung P., Klein H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008;77:229–257. doi: 10.1146/annurev.biochem.77.061306.125255. [PubMed] [CrossRef]

87. Moynahan M.E., Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell Biol. 2010;11:196–207. doi: 10.1038/nrm2851.[PMC free article] [PubMed] [CrossRef]

88. Symington L.S., Gautier J. Double-strand break end resection and repair pathway choice. Annu. Rev. Genet. 2011;45:247–271. doi: 10.1146/annurev-genet-110410-132435. [PubMed] [CrossRef]

89. Bakr A., Oing C., Köcher S., Borgmann K., Dornreiter I., Petersen C., Dikomey E., Mansour W.Y. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 2015;43:3154–3166. doi: 10.1093/nar/gkv160. [PMC free article] [PubMed][CrossRef]

90. Dahm-Daphi J., Hubbe P., Horvath F., El-Awady R.A., Bouffard K.E., Powell S.N., Willers H. Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53. Oncogene. 2005;24:1663–1672. doi: 10.1038/sj.onc.1208396.[PubMed] [CrossRef]

91. Menon V., Povirk L. Involvement of p53 in the repair of DNA double strand breaks: Multifaceted roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ) Subcell. Biochem. 2014;85:321–336. [PMC free article] [PubMed]

92. Panier S., Boulton S.J. Double-strand break repair: 53BP1 comes into focus. Nat. Rev. Mol. Cell Biol. 2014;15:7–18. doi: 10.1038/nrm3719. [PubMed] [CrossRef]

93. Bau D.-T., Mau Y.-C., Shen C.-Y. The role of BRCA1 in non-homologous end-joining. Cancer Lett. 2006;240:1–8. doi: 10.1016/j.canlet.2005.08.003. [PubMed] [CrossRef]

94. Welcsh P.L., King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 2001;10:705–713. doi: 10.1093/hmg/10.7.705. [PubMed] [CrossRef]

95. Haupt S., Raghu D., Haupt Y. Mutant p53 drives cancer by subverting multiple tumor suppression pathways. Front. Oncol. 2016;6:12. doi: 10.3389/fonc.2016.00012. [PMC free article] [PubMed][CrossRef]

96. Guirouilh-Barbat J., Lambert S., Bertrand P., Lopez B.S. Is homologous recombination really an error-free process? Front. Genet. 2014;5 doi: 10.3389/fgene.2014.00175. [PMC free article] [PubMed][CrossRef]

97. Sharma S., Javadekar S.M., Pandey M., Srivastava M., Kumari R., Raghavan S.C. Homology and enzymatic requirements of microhomology-dependent alternative end joining. Cell Death Dis. 2015;6:e1697. doi: 10.1038/cddis.2015.58. [PMC free article] [PubMed] [CrossRef]

98. Aparicio T., Baer R., Gautier J. DNA double-strand break repair pathway choice and cancer. DNA Repair. 2014;19:169–175. doi: 10.1016/j.dnarep.2014.03.014. [PMC free article] [PubMed] [CrossRef]

99. Sinha S., Villarreal D., Shim E.Y., Lee S.E. Risky business: Microhomology-mediated end joining. Mutat. Res. 2016 doi: 10.1016/j.mrfmmm.2015.12.005. [PMC free article] [PubMed] [CrossRef]

100. Kent T., Chandramouly G., McDevitt S.M., Ozdemir A.Y., Pomerantz R.T. Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ Nat. Struct. Mol. Biol. 2015;22:230–237. doi: 10.1038/nsmb.2961. [PMC free article] [PubMed] [CrossRef]

101. Lemée F., Bergoglio V., Fernandez-Vidal A., Machado-Silva A., Pillaire M.-J., Bieth A., Gentil C., Baker L., Martin A.-L., Leduc C., et al. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc. Natl. Acad. Sci. USA. 2010;107:13390–13395. doi: 10.1073/pnas.0910759107. [PMC free article] [PubMed] [CrossRef]

102. Higgins G.S., Harris A.L., Prevo R., Helleday T., McKenna W.G., Buffa F.M. Overexpression of POLQ confers a poor prognosis in early breast cancer patients. Oncotarget. 2010;1:175–184. doi: 10.18632/oncotarget.124. [PMC free article] [PubMed] [CrossRef]

103. Lee S.D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Investig. 1998;101:927–934. doi: 10.1172/JCI1910. [PMC free article] [PubMed] [CrossRef]

104. Tuder R.M., Radisavljevic Z., Shroyer K.R., Polak J.M., Voelkel N.F. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1998;158:1999–2001. doi: 10.1164/ajrccm.158.6.9805002. [PubMed] [CrossRef]

105. Yeager M.E., Halley G.R., Golpon H.A., Voelkel N.F., Tuder R.M. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res. 2001;88:E2–E11. doi: 10.1161/01.RES.88.1.e2. [PubMed] [CrossRef]

106. Aldred M.A., Comhair S.A., Varella-Garcia M., Asosingh K., Xu W., Noon G.P., Thistlethwaite P.A., Tuder R.M., Erzurum S.C., Geraci M.W., et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2010;182:1153–1160. doi: 10.1164/rccm.201003-0491OC. [PMC free article] [PubMed] [CrossRef]

107. Federici C., Drake K.M., Rigelsky C.M., McNelly L.N., Meade S.L., Comhair S.A.A., Erzurum S.C., Aldred M.A. Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 2015;192:219–228. doi: 10.1164/rccm.201411-2128OC. [PMC free article][PubMed] [CrossRef]

108. Simonneau G., Gatzoulis M.A., Adatia I., Celermajer D., Denton C., Ghofrani A., Gomez Sanchez M.A., Krishna Kumar R., Landzberg M., Machado R.F., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013;62:D34–D41. doi: 10.1016/j.jacc.2013.10.029. [PubMed][CrossRef]

109. Sanchez O., Sitbon O., Jaïs X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130:182–189. doi: 10.1378/chest.130.1.182. [PubMed] [CrossRef]

110. Karmochkine M., Wechsler B., Godeau P., Brenot F., Jagot J.L., Simonneau G. Improvement of severe pulmonary hypertension in a patient with SLE. Ann. Rheum. Dis. 1996;55:561–562. doi: 10.1136/ard.55.8.561. [PMC free article] [PubMed] [CrossRef]

111. Meloche J., Renard S., Provencher S., Bonnet S. Anti-inflammatory and immunosuppressive agents in PAH. Handb. Exp. Pharmacol. 2013;218:437–476. [PubMed]

112. Jouve P., Humbert M., Chauveheid M.-P., Jaïs X., Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir. Med. 2007;101:353–355. doi: 10.1016/j.rmed.2006.04.026.[PubMed] [CrossRef]

113. Dorfmüller P., Perros F., Balabanian K., Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 2003;22:358–363. doi: 10.1183/09031936.03.00038903. [PubMed] [CrossRef]

114. Perros F., Dorfmüller P., Montani D., Hammad H., Waelput W., Girerd B., Raymond N., Mercier O., Mussot S., Cohen-Kaminsky S., et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2012;185:311–321. doi: 10.1164/rccm.201105-0927OC.[PubMed] [CrossRef]

115. Cohen-Kaminsky S., Ranchoux B., Perros F. CXCL13 in tertiary lymphoid tissues: Sites of production are different from sites of functional localization. Am. J. Respir. Crit. Care Med. 2014;189:369–370. doi: 10.1164/rccm.201307-1389LE. [PubMed] [CrossRef]

116. Price L.C., Wort S.J., Perros F., Dorfmüller P., Huertas A., Montani D., Cohen-Kaminsky S., Humbert M. Inflammation in pulmonary arterial hypertension. Chest. 2012;141:210–221. doi: 10.1378/chest.11-0793. [PubMed] [CrossRef]

117. Perros F., Cohen-Kaminsky S., Gambaryan N., Girerd B., Raymond N., Klingelschmitt I., Huertas A., Mercier O., Fadel E., Simonneau G., et al. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am. J. Respir. Crit. Care Med. 2013;187:189–196. doi: 10.1164/rccm.201208-1364OC. [PubMed] [CrossRef]

118. Montani D., Perros F., Gambaryan N., Girerd B., Dorfmuller P., Price L.C., Huertas A., Hammad H., Lambrecht B., Simonneau G., et al. C-Kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2011;184:116–123. doi: 10.1164/rccm.201006-0905OC. [PubMed] [CrossRef]

119. Perros F., Dorfmüller P., Souza R., Durand-Gasselin I., Mussot S., Mazmanian M., Hervé P., Emilie D., Simonneau G., Humbert M. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur. Respir. J. 2007;29:462–468. doi: 10.1183/09031936.00094706. [PubMed] [CrossRef]

120. Humbert M., Monti G., Brenot F., Sitbon O., Portier A., Grangeot-Keros L., Duroux P., Galanaud P., Simonneau G., Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1995;151:1628–1631. doi: 10.1164/ajrccm.151.5.7735624. [PubMed] [CrossRef]

121. Soon E., Holmes A.M., Treacy C.M., Doughty N.J., Southgate L., Machado R.D., Trembath R.C., Jennings S., Barker L., Nicklin P., et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920–927. doi: 10.1161/CIRCULATIONAHA.109.933762. [PubMed] [CrossRef]

122. Hautefort A., Girerd B., Montani D., Cohen-Kaminsky S., Price L., Lambrecht B.N., Humbert M., Perros F. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest. 2015;147:1610–1620. doi: 10.1378/chest.14-1678. [PubMed] [CrossRef]

123. Itoh T., Nagaya N., Ishibashi-Ueda H., Kyotani S., Oya H., Sakamaki F., Kimura H., Nakanishi N. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology. 2006;11:158–163. doi: 10.1111/j.1440-1843.2006.00821.x. [PubMed] [CrossRef]

124. Golembeski S.M., West J., Tada Y., Fagan K.A. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest. 2005;128:572S–573S. doi: 10.1378/chest.128.6_suppl.572S-a. [PubMed] [CrossRef]

125. Miyata M., Sakuma F., Yoshimura A., Ishikawa H., Nishimaki T., Kasukawa R. Pulmonary hypertension in rats. 2. Role of interleukin-6. Int. Arch. Allergy Immunol. 1995;108:287–291. doi: 10.1159/000237166. [PubMed] [CrossRef]

126. Steiner M.K., Syrkina O.L., Kolliputi N., Mark E.J., Hales C.A., Waxman A.B. Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 2009;104:236–244. doi: 10.1161/CIRCRESAHA.108.182014. [PMC free article] [PubMed] [CrossRef]

127. Savale L., Tu L., Rideau D., Izziki M., Maitre B., Adnot S., Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 2009;10:6. doi: 10.1186/1465-9921-10-6. [PMC free article] [PubMed] [CrossRef]

128. Meira L.B., Bugni J.M., Green S.L., Lee C.-W., Pang B., Borenshtein D., Rickman B.H., Rogers A.B., Moroski-Erkul C.A., McFaline J.L., et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Investig. 2008;118:2516–2525. doi: 10.1172/JCI35073.[PMC free article] [PubMed] [CrossRef]

129. Wheelhouse N.M., Chan Y.-S., Gillies S.E., Caldwell H., Ross J.A., Harrison D.J., Prost S. TNF-α induced DNA damage in primary murine hepatocytes. Int. J. Mol. Med. 2003;12:889–894. doi: 10.3892/ijmm.12.6.889. [PubMed] [CrossRef]

130. Suematsu N., Tsutsui H., Wen J., Kang D., Ikeuchi M., Ide T., Hayashidani S., Shiomi T., Kubota T., Hamasaki N., et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation. 2003;107:1418–1423. doi: 10.1161/01.CIR.0000055318.09997.1F. [PubMed] [CrossRef]

131. Poltz R., Naumann M. Dynamics of p53 and NF-κB regulation in response to DNA damage and identification of target proteins suitable for therapeutic intervention. BMC Syst. Biol. 2012;6:125. doi: 10.1186/1752-0509-6-125. [PMC free article] [PubMed] [CrossRef]

132. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–466. doi: 10.1038/nature02924. [PubMed] [CrossRef]

133. Kidane D., Chae W.J., Czochor J., Eckert K.A., Glazer P.M., Bothwell A.L.M., Sweasy J.B. Interplay between DNA repair and inflammation, and the link to cancer. Crit. Rev. Biochem. Mol. Biol. 2014;49:116–139. doi: 10.3109/10409238.2013.875514. [PMC free article] [PubMed] [CrossRef]

134. Hussain S.P., Harris C.C. Inflammation and cancer: An ancient link with novel potentials. Int. J. Cancer. 2007;121:2373–2380. doi: 10.1002/ijc.23173. [PubMed] [CrossRef]

135. Schetter A.J., Heegaard N.H.H., Harris C.C. Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31:37–49. doi: 10.1093/carcin/bgp272.[PMC free article] [PubMed] [CrossRef]

136. Pálmai-Pallag T., Bachrati C.Z. Inflammation-induced DNA damage and damage-induced inflammation: A vicious cycle. Microbes Infect. Inst. Pasteur. 2014;16:822–832. doi: 10.1016/j.micinf.2014.10.001. [PubMed] [CrossRef]

137. Olivieri F., Albertini M.C., Orciani M., Ceka A., Cricca M., Procopio A.D., Bonafè M. DNA damage response (DDR) and senescence: Shuttled inflamma-miRNAs on the stage of inflamm-aging. Oncotarget. 2015;6:35509–35521. [PMC free article] [PubMed]

138. Yun U.J., Park S.E., Jo Y.S., Kim J., Shin D.Y. DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett. 2012;323:155–160. doi: 10.1016/j.canlet.2012.04.003. [PubMed] [CrossRef]

139. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.-Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–113. doi: 10.1016/j.ccr.2009.01.001.[PMC free article] [PubMed] [CrossRef]

140. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009;15:79–80. doi: 10.1016/j.ccr.2009.01.009. [PMC free article] [PubMed] [CrossRef]

141. Morrell N.W. Pulmonary hypertension due to BMPR2 mutation: A new paradigm for tissue remodeling? Proc. Am. Thorac. Soc. 2006;3:680–686. doi: 10.1513/pats.200605-118SF. [PubMed][CrossRef]

142. Hagen M., Fagan K., Steudel W., Carr M., Lane K., Rodman D.M., West J. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007;292:L1473–L1479. doi: 10.1152/ajplung.00197.2006. [PubMed] [CrossRef]

143. Perros F., Bonnet S. Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world. Am. J. Respir. Crit. Care Med. 2015;192:777–779. doi: 10.1164/rccm.201506-1115ED. [PubMed] [CrossRef]

144. Soon E., Crosby A., Southwood M., Yang P., Tajsic T., Toshner M., Appleby S., Shanahan C.M., Bloch K.D., Pepke-Zaba J., et al. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2015;192:859–872. doi: 10.1164/rccm.201408-1509OC. [PMC free article] [PubMed] [CrossRef]

145. Paulin R., Meloche J., Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAK-STAT. 2012;1:223–233. doi: 10.4161/jkst.22366. [PMC free article] [PubMed] [CrossRef]

146. Perros F., Montani D., Dorfmüller P., Durand-Gasselin I., Tcherakian C., Le Pavec J., Mazmanian M., Fadel E., Mussot S., Mercier O., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008;178:81–88. doi: 10.1164/rccm.200707-1037OC. [PubMed] [CrossRef]

147. Aggarwal S., Gross C.M., Sharma S., Fineman J.R., Black S.M. Reactive oxygen species in pulmonary vascular remodeling. Compr. Physiol. 2013;3:1011–1034. [PMC free article] [PubMed]

148. Bowers R., Cool C., Murphy R.C., Tuder R.M., Hopken M.W., Flores S.C., Voelkel N.F. Oxidative stress in severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004;169:764–769. doi: 10.1164/rccm.200301-147OC. [PubMed] [CrossRef]

149. Demarco V.G., Whaley-Connell A.T., Sowers J.R., Habibi J., Dellsperger K.C. Contribution of oxidative stress to pulmonary arterial hypertension. World J. Cardiol. 2010;2:316–324. doi: 10.4330/wjc.v2.i10.316. [PMC free article] [PubMed] [CrossRef]

150. Dorfmüller P., Chaumais M.-C., Giannakouli M., Durand-Gasselin I., Raymond N., Fadel E., Mercier O., Charlotte F., Montani D., Simonneau G., et al. Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir. Res. 2011;12:119. doi: 10.1186/1465-9921-12-119. [PMC free article] [PubMed] [CrossRef]

151. Black S.M., DeVol J.M., Wedgwood S. Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation. Am. J. Physiol. Cell Physiol. 2008;294:C345–C354. doi: 10.1152/ajpcell.00216.2007. [PMC free article][PubMed] [CrossRef]

152. Montisano D.F., Mann T., Spragg R.G. H_2O_2 increases expression of pulmonary artery endothelial cell platelet-derived growth factor mRNA. J. Appl. Physiol. 1992;73:2255–2262. [PubMed]

153. Wedgwood S., Dettman R.W., Black S.M. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001;281:L1058–1067. [PubMed]

154. Block K., Gorin Y., Hoover P., Williams P., Chelmicki T., Clark R.A., Yoneda T., Abboud H.E. NAD(P)H oxidases regulate HIF-2alpha protein expression. J. Biol. Chem. 2007;282:8019–8026. doi: 10.1074/jbc.M611569200. [PubMed] [CrossRef]

155. Chandel N.S., McClintock D.S., Feliciano C.E., Wood T.M., Melendez J.A., Rodriguez A.M., Schumacker P.T. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia A MECHANISM OF O_2 SENSING. J. Biol. Chem. 2000;275:25130–25138. doi: 10.1074/jbc.M001914200. [PubMed] [CrossRef]

156. Gale D.P., Harten S.K., Reid C.D.L., Tuddenham E.G.D., Maxwell P.H. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutation. Blood. 2008;112:919–921. doi: 10.1182/blood-2008-04-153718. [PubMed] [CrossRef]

157. Brusselmans K., Compernolle V., Tjwa M., Wiesener M.S., Maxwell P.H., Collen D., Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor–2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J. Clin. Investig. 2003;111:1519–1527. doi: 10.1172/JCI15496. [PMC free article] [PubMed] [CrossRef]

158. Cheng T.H., Shih N.L., Chen S.Y., Loh S.H., Cheng P.Y., Tsai C.S., Liu S.H., Wang D.L., Chen J.J. Reactive oxygen species mediate cyclic strain-induced endothelin-1 gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in endothelial cells. J. Mol. Cell. Cardiol. 2001;33:1805–1814. doi: 10.1006/jmcc.2001.1444. [PubMed] [CrossRef]

159. Tate R.M., Morris H.G., Schroeder W.R., Repine J.E. Oxygen metabolites stimulate thromboxane production and vasoconstriction in isolated saline-perfused rabbit lungs. J. Clin. Investig. 1984;74:608–613. doi: 10.1172/JCI111458. [PMC free article] [PubMed] [CrossRef]

160. Lee D.S., McCallum E.A., Olson D.M. Effects of reactive oxygen species on prostacyclin production in perinatal rat lung cells. J. Appl. Physiol. 1989;66:1321–1327. [PubMed]

161. Brito R., Castillo G., González J., Valls N., Rodrigo R. Oxidative stress in hypertension: Mechanisms and therapeutic opportunities. Exp. Clin. Endocrinol. Diabetes. 2015;123:325–335. doi: 10.1055/s-0035-1548765. [PubMed] [CrossRef]

162. Weissmann N., Winterhalder S., Nollen M., Voswinckel R., Quanz K., Ghofrani H.A., Schermuly R.T., Seeger W., Grimminger F. NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001;280:L638–L645.[PubMed]

163. Waypa G.B., Marks J.D., Mack M.M., Boriboun C., Mungai P.T., Schumacker P.T. Mitochondrial Reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. Circ. Res. 2002;91:719–726. doi: 10.1161/01.RES.0000036751.04896.F1. [PubMed] [CrossRef]

164. Hoshikawa Y., Ono S., Suzuki S., Tanita T., Chida M., Song C., Noda M., Tabata T., Voelkel N.F., Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J. Appl. Physiol. 2001;90:1299–1306. [PubMed]

165. Jankov R.P., Kantores C., Pan J., Belik J. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am. J. Physiol. 2008;294:L233–L245. doi: 10.1152/ajplung.00166.2007. [PubMed] [CrossRef]

166. Rafikova O., Rafikov R., Kangath A., Qu N., Aggarwal S., Sharma S., Desai J., Fields T., Ludewig B., Yuan J.X.-Y., et al. Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension. Free Radic. Biol. Med. 2016 doi: 10.1016/j.freeradbiomed.2016.02.029.[PMC free article] [PubMed] [CrossRef]

167. Rawat D.K., Alzoubi A., Gupte R., Chettimada S., Watanabe M., Kahn A.G., Okada T., McMurtry I.F., Gupte S.A. Increased reactive oxygen species, metabolic maladaptation, and autophagy contribute to pulmonary arterial hypertension-induced ventricular hypertrophy and diastolic heart failure. Hypertension. 2014;64:1266–1274. doi: 10.1161/HYPERTENSIONAHA.114.03261. [PubMed] [CrossRef]

168. Liu J.Q., Zelko I.N., Erbynn E.M., Sham J.S.K., Folz R.J. Hypoxic pulmonary hypertension: Role of superoxide and NADPH oxidase (gp91phox) Am. J. Physiol. Lung Cell. Mol. Physiol. 2006;290:L2–L10. doi: 10.1152/ajplung.00135.2005. [PubMed] [CrossRef]

169. Matsui H., Shimosawa T., Itakura K., Guanqun X., Ando K., Fujita T. Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation. 2004;109:2246–2251. doi: 10.1161/01.CIR.0000127950.13380.FD. [PubMed] [CrossRef]

170. Liu M., Wang Y., Zheng L., Zheng W., Dong K., Chen S., Zhang B., Li Z. Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α Respir. Physiol. Neurobiol. 2014;201:38–46. doi: 10.1016/j.resp.2014.06.001. [PubMed] [CrossRef]

171. Zhang B., Niu W., Xu D., Li Y., Liu M., Wang Y., Luo Y., Zhao P., Liu Y., Dong M., et al. Oxymatrine prevents hypoxia- and monocrotaline-induced pulmonary hypertension in rats. Free Radic. Biol. Med. 2014;69:198–207. doi: 10.1016/j.freeradbiomed.2014.01.013. [PubMed] [CrossRef]

172. Chaumais M.-C., Ranchoux B., Montani D., Dorfmüller P., Tu L., Lecerf F., Raymond N., Guignabert C., Price L., Simonneau G., et al. *N*-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respir. Res. 2014;15:65. doi: 10.1186/1465-9921-15-65. [PMC free article] [PubMed][CrossRef]

173. Mittal M., Roth M., König P., Hofmann S., Dony E., Goyal P., Selbitz A.-C., Schermuly R.T., Ghofrani H.A., Kwapiszewska G., et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ. Res. 2007;101:258–267. doi: 10.1161/CIRCRESAHA.107.148015. [PubMed] [CrossRef]

174. Babior B.M. The NADPH oxidase of endothelial cells. IUBMB Life. 2000;50:267–269. doi: 10.1080/15216540051080976. [PubMed] [CrossRef]

175. Vignais P.V. The superoxide-generating NADPH oxidase: Structural aspects and activation mechanism. Cell. Mol. Life Sci. 2002;59:1428–1459. doi: 10.1007/s00018-002-8520-9. [PubMed][CrossRef]

176. Fresquet F., Pourageaud F., Leblais V., Brandes R.P., Savineau J.-P., Marthan R., Muller B. Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia. Br. J. Pharmacol. 2006;148:714–723. doi: 10.1038/sj.bjp.0706779. [PMC free article] [PubMed][CrossRef]

177. Paravicini T.M., Gulluyan L.M., Dusting G.J., Drummond G.R. Increased NADPH oxidase activity, gp91phox expression, and endothelium-dependent vasorelaxation during neointima formation in rabbits. Circ. Res. 2002;91:54–61. doi: 10.1161/01.RES.0000024106.81401.95. [PubMed] [CrossRef]

178. Li S., Tabar S.S., Malec V., Eul B.G., Klepetko W., Weissmann N., Grimminger F., Seeger W., Rose F., Hänze J. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. Antioxid. Redox Signal. 2008;10:1687–1698. doi: 10.1089/ars.2008.2035. [PubMed] [CrossRef]

179. Sturrock A., Cahill B., Norman K., Huecksteadt T.P., Hill K., Sanders K., Karwande S.V., Stringham J.C., Bull D.A., Gleich M., et al. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006;290:L661–L673. doi: 10.1152/ajplung.00269.2005. [PubMed][CrossRef]

180. Selimovic N., Bergh C.-H., Andersson B., Sakiniene E., Carlsten H., Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur. Respir. J. 2009;34:662–668. doi: 10.1183/09031936.00174908. [PubMed] [CrossRef]

181. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Investig. 2003;111:1201–1209. doi: 10.1172/JCI200314172. [PMC free article][PubMed] [CrossRef]

182. Morris C.R., Kato G.J., Poljakovic M., Wang X., Blackwelder W.C., Sachdev V., Hazen S.L., Vichinsky E.P., Morris S.M., Gladwin M.T. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294:81–90. doi: 10.1001/jama.294.1.81. [PMC free article] [PubMed] [CrossRef]

183. Pullamsetti S., Kiss L., Ghofrani H.A., Voswinckel R., Haredza P., Klepetko W., Aigner C., Fink L., Muyal J.P., Weissmann N., et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2005;19:1175–1177. doi: 10.1186/1471-2210-5-S1-P45. [PubMed] [CrossRef]

184. Iannone L., Zhao L., Dubois O., Duluc L., Rhodes C.J., Wharton J., Wilkins M.R., Leiper J., Wojciak-Stothard B. miR-21/DDAH1 pathway regulates pulmonary vascular responses to hypoxia. Biochem. J. 2014;462:103–112. doi: 10.1042/BJ20140486. [PubMed] [CrossRef]

185. Li X.-H., Peng J., Tan N., Wu W.-H., Li T.-T., Shi R.-Z., Li Y.-J. Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension. Vascul. Pharmacol. 2010;53:223–229. doi: 10.1016/j.vph.2010.09.002. [PubMed] [CrossRef]

186. Archer S.L., Marsboom G., Kim G.H., Zhang H.J., Toth P.T., Svensson E.C., Dyck J.R.B., Gomberg-Maitland M., Thébaud B., Husain A.N., et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 (SOD2) in pulmonary arterial hypertension. Circulation. 2010;121:2661–2671. doi: 10.1161/CIRCULATIONAHA.109.916098. [PMC free article] [PubMed] [CrossRef]

187. Reis G.S., Augusto V.S., Silveira A.P.C., Jordão A.A., Baddini-Martinez J., Poli Neto O., Rodrigues A.J., Evora P.R.B. Oxidative-stress biomarkers in patients with pulmonary hypertension. Pulm. Circ. 2013;3:856–861. doi: 10.1086/674764. [PMC free article] [PubMed] [CrossRef]

188. Cracowski J.L., Cracowski C., Bessard G., Pepin J.L., Bessard J., Schwebel C., Stanke-Labesque F., Pison C. Increased lipid peroxidation in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2001;164:1038–1042. doi: 10.1164/ajrccm.164.6.2104033. [PubMed] [CrossRef]

189. Wong C.-M., Bansal G., Pavlickova L., Marcocci L., Suzuki Y.J. Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid. Redox Signal. 2013;18:1789–1796. doi: 10.1089/ars.2012.4568. [PMC free article] [PubMed] [CrossRef]

190. Tabima D.M., Frizzell S., Gladwin M.T. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic. Biol. Med. 2012;52:1970–1986. doi: 10.1016/j.freeradbiomed.2012.02.041.[PMC free article] [PubMed] [CrossRef]

191. Crosswhite P., Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J. Hypertens. 2010;28:201–212. doi: 10.1097/HJH.0b013e328332bcdb. [PMC free article][PubMed] [CrossRef]

192. Yasui M., Kanemaru Y., Kamoshita N., Suzuki T., Arakawa T., Honma M. Tracing the fates of site-specifically introduced DNA adducts in the human genome. DNA Repair. 2014;15:11–20. doi: 10.1016/j.dnarep.2014.01.003. [PubMed] [CrossRef]

193. Martinez G.R., Loureiro A.P.M., Marques S.A., Miyamoto S., Yamaguchi L.F., Onuki J., Almeida E.A., Garcia C.C.M., Barbosa L.F., Medeiros M.H.G., et al. Oxidative and alkylating damage in DNA. Mutat. Res. 2003;544:115–127. doi: 10.1016/j.mrrev.2003.05.005. [PubMed] [CrossRef]

194. Klaunig J.E., Kamendulis L.M., Hocevar B.A. Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 2010;38:96–109. doi: 10.1177/0192623309356453. [PubMed] [CrossRef]

195. Gurtner H.P. Aminorex and pulmonary hypertension. A review. Cor et Vasa. 1985;27:160–171.[PubMed]

196. Simonneau G., Fartoukh M., Sitbon O., Humbert M., Jagot J.L., Hervé P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest. 1998;114:195S–199S. doi: 10.1378/chest.114.3_Supplement.195S. [PubMed] [CrossRef]

197. Douglas J.G., Munro J.F., Kitchin A.H., Muir A.L., Proudfoot A.T. Pulmonary hypertension and fenfluramine. Br. Med. J. Clin. Res. Ed. 1981;283:881–883. doi: 10.1136/bmj.283.6296.881.[PMC free article] [PubMed] [CrossRef]

198. Sitbon O., Humbert M., Simonneau G. Pulmonary Circulation: Diseases and Their Treatment. 3rd ed. CRC Press; Boca Raton, FL, USA: 2011. Pulmonary hypertension related to appetite suppressants.

199. Chin K.M., Channick R.N., Rubin L.J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006;130:1657–1663. doi: 10.1378/chest.130.6.1657. [PubMed] [CrossRef]

200. Schaiberger P.H., Kennedy T.C., Miller F.C., Gal J., Petty T.L. Pulmonary hypertension associated with long-term inhalation of “crank” methamphetamine. Chest. 1993;104:614–616. doi: 10.1378/chest.104.2.614. [PubMed] [CrossRef]

201. Montani D., Seferian A., Savale L., Simonneau G., Humbert M. Drug-induced pulmonary arterial hypertension: A recent outbreak. Eur. Respir. Rev. 2013;22:244–250. doi: 10.1183/09059180.00003313.[PubMed] [CrossRef]

202. Gonçalves C.L., Rezin G.T., Ferreira G.K., Jeremias I.C., Cardoso M.R., Valvassori S.S., Munhoz B.J.P., Borges G.D., Bristot B.N., Leffa D.D., et al. Effects of acute and chronic administration of fenproporex on DNA damage parameters in young and adult rats. Mol. Cell. Biochem. 2013;380:171–176. doi: 10.1007/s11010-013-1670-2. [PubMed] [CrossRef]

203. Alvarenga T.A., Andersen M.L., Ribeiro D.A., Araujo P., Hirotsu C., Costa J.L., Battisti M.C., Tufik S. Single exposure to cocaine or ecstasy induces DNA damage in brain and other organs of mice. Addict. Biol. 2010;15:96–99. doi: 10.1111/j.1369-1600.2009.00179.x. [PubMed] [CrossRef]

204. Andreazza A.C., Kauer-Sant'Anna M., Frey B.N., Stertz L., Zanotto C., Ribeiro L., Giasson K., Valvassori S.S., Réus G.Z., Salvador M., et al. Effects of mood stabilizers on DNA damage in an animal model of mania. J. Psychiatry Neurosci. 2008;33:516–524. [PMC free article] [PubMed]

205. Agarwal K., Mukherjee A., Sharma A., Sharma R., Bhardwaj K.R., Sen S. Clastogenic effect of fenfluramine in mice bone marrow cells *in vivo*. Environ. Mol. Mutagen. 1992;19:323–326. doi: 10.1002/em.2850190410. [PubMed] [CrossRef]

206. Johnson Z., Venters J., Guarraci F.A., Zewail-Foote M. Methamphetamine induces DNA damage in specific regions of the female rat brain. Clin. Exp. Pharmacol. Physiol. 2015;42:570–575. doi: 10.1111/1440-1681.12404. [PubMed] [CrossRef]

207. Nakagawa Y., Tayama S., Ogata A., Suzuki T., Ishii H. ATP-generating glycolytic substrates prevent *N*-nitrosofenfluramine-induced cytotoxicity in isolated rat hepatocytes. Chem. Biol. Interact. 2006;164:93–101. doi: 10.1016/j.cbi.2006.08.024. [PubMed] [CrossRef]

208. Parolini M., Magni S., Castiglioni S., Binelli A. Amphetamine exposure imbalanced antioxidant activity in the bivalve *Dreissena polymorpha* causing oxidative and genetic damage. Chemosphere. 2016;144:207–213. doi: 10.1016/j.chemosphere.2015.08.025. [PubMed] [CrossRef]

209. Da Silva C.J., dos Santos J.E., Satie Takahashi C. An evaluation of the genotoxic and cytotoxic effects of the anti-obesity drugs sibutramine and fenproporex. Hum. Exp. Toxicol. 2010;29:187–197. doi: 10.1177/0960327109358732. [PubMed] [CrossRef]

210. Perfeito R., Cunha-Oliveira T., Rego A.C. Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic. Biol. Med. 2013;62:186–201. doi: 10.1016/j.freeradbiomed.2013.05.042. [PubMed][CrossRef]

211. Bengel D., Isaacs K.R., Heils A., Lesch K.P., Murphy D.L. The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells. Neuroreport. 1998;9:2989–2993. doi: 10.1097/00001756-199809140-00013. [PubMed] [CrossRef]

212. Eddahibi S., Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: Lessons for the future in pathogenesis. Respir. Res. 2002;3:9. doi: 10.1186/rr181.[PMC free article] [PubMed] [CrossRef]

213. Alwan S., Bandoli G., Chambers C.D. Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. Clin. Pharmacol. Ther. 2016 doi: 10.1002/cpt.376.[PubMed] [CrossRef]

214. Fornaro E., Li D., Pan J., Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am. J. Respir. Crit. Care Med. 2007;176:1035–1040. doi: 10.1164/rccm.200701-163OC. [PubMed] [CrossRef]

215. Sadoughi A., Roberts K.E., Preston I.R., Lai G.P., McCollister D.H., Farber H.W., Hill N.S. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest. 2013;144:531–541. doi: 10.1378/chest.12-2081. [PMC free article] [PubMed] [CrossRef]

216. Dhalla I.A., Juurlink D.N., Gomes T., Granton J.T., Zheng H., Mamdani M.M. Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: A case-control study. Chest. 2012;141:348–353. doi: 10.1378/chest.11-0426. [PubMed] [CrossRef]

217. Eddahibi S., Humbert M., Fadel E., Raffestin B., Darmon M., Capron F., Simonneau G., Dartevelle P., Hamon M., Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Investig. 2001;108:1141–1150. doi: 10.1172/JCI200112805. [PMC free article] [PubMed] [CrossRef]

218. Eddahibi S., Hanoun N., Lanfumey L., Lesch K.P., Raffestin B., Hamon M., Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Investig. 2000;105:1555–1562. doi: 10.1172/JCI8678. [PMC free article] [PubMed] [CrossRef]

219. Gürbüzel M., Oral E., Kizilet H., Halici Z., Gulec M. Genotoxic evaluation of selective serotonin-reuptake inhibitors by use of the somatic mutation and recombination test in *Drosophila melanogaster*. Mutat. Res. 2012;748:17–20. doi: 10.1016/j.mrgentox.2012.06.004. [PubMed] [CrossRef]

220. Djordjevic J., Djordjevic A., Adzic M., Elaković I., Matić G., Radojcic M.B. Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver. Eur. J. Pharmacol. 2011;659:61–66. doi: 10.1016/j.ejphar.2011.03.003. [PubMed] [CrossRef]

221. Alzahrani H.A.S. Sister chromatid exchanges and sperm abnormalities produced by antidepressant drug fluoxetine in mouse treated *in vivo*. Eur. Rev. Med. Pharmacol. Sci. 2012;16:2154–2161. [PubMed]

222. Riggin L., Koren G. Effects of selective serotonin reuptake inhibitors on sperm and male fertility. Can. Fam. Physician. 2015;61:529–530.

223. Attia S.M., Bakheet S.A. Citalopram at the recommended human doses after long-term treatment is genotoxic for male germ cell. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2013;53:281–285. doi: 10.1016/j.fct.2012.11.051. [PubMed] [CrossRef]

224. Tanrikut C., Feldman A.S., Altemus M., Paduch D.A., Schlegel P.N. Adverse effect of paroxetine on sperm. Fertil. Steril. 2010;94:1021–1026. doi: 10.1016/j.fertnstert.2009.04.039. [PubMed] [CrossRef]

225. Fox B.D., Azoulay L., Dell'Aniello S., Langleben D., Lapi F., Benisty J., Suissa S. The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension. Can. J. Cardiol. 2014;30:1633–1639. doi: 10.1016/j.cjca.2014.09.031. [PubMed] [CrossRef]

226. Czarny P., Kwiatkowski D., Kacperska D., Kawczyńska D., Talarowska M., Orzechowska A., Bielecka-Kowalska A., Szemraj J., Gałecki P., Śliwiński T. Elevated level of DNA damage and impaired repair of oxidative DNA damage in patients with recurrent depressive disorder. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2015;21:412–418. [PMC free article] [PubMed]

227. Black C.N., Bot M., Scheffer P.G., Cuijpers P., Penninx B.W.J.H. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology. 2015;51:164–175. doi: 10.1016/j.psyneuen.2014.09.025. [PubMed] [CrossRef]

228. Lacave R., Larsen C.-J., Robert J. Cancérologie Fondamentale. John Libbey Eurotext; Paris, France: 2005.

229. Kondo N., Takahashi A., Ono K., Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J. Nucleic Acids. 2010;2010:543531. doi: 10.4061/2010/543531. [PMC free article] [PubMed][CrossRef]

230. Fu D., Calvo J.A., Samson L.D. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer. 2012;12:104–120. doi: 10.1038/nrc3185. [PMC free article] [PubMed][CrossRef]

231. Hoorn C.M., Wagner J.G., Petry T.W., Roth R.A. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol. Appl. Pharmacol. 1995;130:87–94. doi: 10.1006/taap.1995.1012. [PubMed][CrossRef]

232. Lushnikova E.L., Molodykh O.P., Nepomnyashchikh L.M., Bakulina A.A., Sorokina Y.A. Ultrastructurural picture of cyclophosphamide-induced damage to the liver. Bull. Exp. Biol. Med. 2011;151:751–756. doi: 10.1007/s10517-011-1432-7. [PubMed] [CrossRef]

233. Ranchoux B., Günther S., Quarck R., Chaumais M.-C., Dorfmüller P., Antigny F., Dumas S.J., Raymond N., Lau E., Savale L., et al. Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. Am. J. Pathol. 2015;185:356–371. doi: 10.1016/j.ajpath.2014.10.021. [PubMed] [CrossRef]

234. Perros F., Günther S., Ranchoux B., Godinas L., Antigny F., Chaumais M.-C., Dorfmüller P., Hautefort A., Raymond N., Savale L., et al. Mitomycin-induced pulmonary veno-occlusive disease: Evidence from human disease and animal models. Circulation. 2015;132:834–847. doi: 10.1161/CIRCULATIONAHA.115.014207. [PubMed] [CrossRef]

235. Montani D., Lau E.M., Dorfmüller P., Girerd B., Jaïs X., Savale L., Perros F., Nossent E., Garcia G., Parent F., et al. Pulmonary veno-occlusive disease. Eur. Respir. J. 2016;47:1518–1534. doi: 10.1183/13993003.00026-2016. [PubMed] [CrossRef]

236. Siegel D., Franklin W.A., Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin. Cancer Res. 1998;4:2065–2070. [PubMed]

237. Cooper J.A., Merrill W.W., Reynolds H.Y. Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity. Am. Rev. Respir. Dis. 1986;134:108–114. [PubMed]

238. Hamano Y., Sugimoto H., Soubasakos M.A., Kieran M., Olsen B.R., Lawler J., Sudhakar A., Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64:1570–1574. doi: 10.1158/0008-5472.CAN-03-3126. [PubMed] [CrossRef]

239. Ohtani T., Nakamura T., Toda K.-I., Furukawa F. Cyclophosphamide enhances TNF-α-induced apoptotic cell death in murine vascular endothelial cell. FEBS Lett. 2006;580:1597–1600. doi: 10.1016/j.febslet.2006.01.092. [PubMed] [CrossRef]

240. Mytilineou C., Kramer B.C., Yabut J.A. Glutathione depletion and oxidative stress. Parkinsonism Relat. Disord. 2002;8:385–387. doi: 10.1016/S1353-8020(02)00018-4. [PubMed] [CrossRef]

241. Srivastava A., Poonkuzhali B., Shaji R.V., George B., Mathews V., Chandy M., Krishnamoorthy R. Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104:1574–1577. doi: 10.1182/blood-2003-11-3778. [PubMed][CrossRef]

242. DeLeve L.D. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology. 1996;24:830–837. doi: 10.1002/hep.510240414. [PubMed][CrossRef]

243. Montani D., Lau E.M., Descatha A., Jaïs X., Savale L., Andujar P., Bensefa-Colas L., Girerd B., Zendah I., Le Pavec J., et al. Occupational exposure to organic solvents: A risk factor for pulmonary veno-occlusive disease. Eur. Respir. J. 2015;46:1721–1731. doi: 10.1183/13993003.00814-2015. [PubMed][CrossRef]

244. Hu C., Jiang L., Geng C., Zhang X., Cao J., Zhong L. Possible involvement of oxidative stress in trichloroethylene-induced genotoxicity in human HepG2 cells. Mutat. Res. 2008;652:88–94. doi: 10.1016/j.mrgentox.2008.01.002. [PubMed] [CrossRef]

245. Roth R.A., Reindel J.F. Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. Adv. Exp. Med. Biol. 1991;283:477–487. [PubMed]

246. Yan C.C., Huxtable R.J. Release of an alkylating metabolite, dehydromonocrotaline, from the isolated liver perfused with the pyrrolizidine alkaloid, monocrotaline. Proc. West. Pharmacol. Soc. 1994;37:107–108. [PubMed]

247. Mattocks A.R., Jukes R. Trapping and measurement of short-lived alkylating agents in a recirculating flow system. Chem. Biol. Interact. 1990;76:19–30. doi: 10.1016/0009-2797(90)90031-H. [PubMed][CrossRef]

248. Meloche J., Pflieger A., Vaillancourt M., Paulin R., Potus F., Zervopoulos S., Graydon C., Courboulin A., Breuils-Bonnet S., Tremblay E., et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014;129:786–797. doi: 10.1161/CIRCULATIONAHA.113.006167. [PubMed][CrossRef]

249. Meloche J., Le Guen M., Potus F., Vinck J., Ranchoux B., Johnson I., Antigny F., Tremblay E., Breuils-Bonnet S., Perros F., et al. miR-223 reverses experimental pulmonary arterial hypertension. Am. J. Physiol. Cell Physiol. 2015;309:C363–C372. doi: 10.1152/ajpcell.00149.2015. [PubMed] [CrossRef]

250. Zhong Z., Wen Z., Darnell J.E. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95–98. doi: 10.1126/science.8140422. [PubMed] [CrossRef]

251. Meloche J., Potus F., Vaillancourt M., Bourgeois A., Johnson I., Deschamps L., Chabot S., Ruffenach G., Henry S., Breuils-Bonnet S., et al. Bromodomain-containing protein 4: The epigenetic origin of pulmonary arterial hypertension. Circ. Res. 2015;117:525–535. doi: 10.1161/CIRCRESAHA.115.307004.[PubMed] [CrossRef]

252. Wang M., Wu W., Wu W., Rosidi B., Zhang L., Wang H., Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34:6170–6182. doi: 10.1093/nar/gkl840. [PMC free article] [PubMed] [CrossRef]

253. Byrne M., Wray J., Reinert B., Wu Y., Nickoloff J., Lee S.-H., Hromas R., Williamson E. Mechanisms of oncogenic chromosomal translocations. Ann. N. Y. Acad. Sci. 2014;1310:89–97. doi: 10.1111/nyas.12370. [PubMed] [CrossRef]

254. Wray J., Williamson E.A., Singh S.B., Wu Y., Cogle C.R., Weinstock D.M., Zhang Y., Lee S.-H., Zhou D., Shao L., et al. PARP1 is required for chromosomal translocations. Blood. 2013;121:4359–4365. doi: 10.1182/blood-2012-10-460527. [PMC free article] [PubMed] [CrossRef]

255. Soni A., Siemann M., Grabos M., Murmann T., Pantelias G.E., Iliakis G. Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res. 2014;42:6380–6392. doi: 10.1093/nar/gku298. [PMC free article] [PubMed][CrossRef]

256. Kumar R. Nuclear Signaling Pathways and Targeting Transcription in Cancer. Springer Science & Business Media; New York, NY, USA: 2013.

257. Hu S., Qu Y., Xu X., Xu Q., Geng J., Xu J. Nuclear survivin and its relationship to DNA damage repair genes in non-small cell lung cancer investigated using tissue array. PLoS ONE. 2013;8:990 doi: 10.1371/annotation/03b700e2-348b-4b1c-b068-4760c32de19e. [PMC free article] [PubMed] [CrossRef]

258. Paulin R., Meloche J., Jacob M.H., Bisserier M., Courboulin A., Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 2011;301:H1798–H1809. doi: 10.1152/ajpheart.00654.2011. [PubMed] [CrossRef]

259. McMurtry M.S., Archer S.L., Altieri D.C., Bonnet S., Haromy A., Harry G., Bonnet S., Puttagunta L., Michelakis E.D. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Investig. 2005;115:1479–1491. doi: 10.1172/JCI23203.[PMC free article] [PubMed] [CrossRef]

260. Li M., Vattulainen S., Aho J., Orcholski M., Rojas V., Yuan K., Helenius M., Taimen P., Myllykangas S., de Jesus Perez V., et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 2014;50:1118–1128. doi: 10.1165/rcmb.2013-0349OC. [PubMed] [CrossRef]

261. De Jesus Perez V.A., Yuan K., Lyuksyutova M.A., Dewey F., Orcholski M.E., Shuffle E.M., Mathur M., Yancy L., Rojas V., Li C.G., et al. Whole-exome sequencing reveals topbp1 as a novel gene in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2014;189:1260–1272. doi: 10.1164/rccm.201310-1749OC. [PMC free article] [PubMed] [CrossRef]

262. Lee Y., Katyal S., Downing S.M., Zhao J., Russell H.R., McKinnon P.J. Neurogenesis requires TopBP1 to prevent catastrophic replicative DNA damage in early progenitors. Nat. Neurosci. 2012;15:819–826. doi: 10.1038/nn.3097. [PMC free article] [PubMed] [CrossRef]

263. Yamane K., Wu X., Chen J. A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival. Mol. Cell. Biol. 2002;22:555–566. doi: 10.1128/MCB.22.2.555-566.2002.[PMC free article] [PubMed] [CrossRef]

264. Mäkiniemi M., Hillukkala T., Tuusa J., Reini K., Vaara M., Huang D., Pospiech H., Majuri I., Westerling T., Mäkelä T.P., et al. BRCT domain-containing protein TopBP1 functions in DNA replication and damage response. J. Biol. Chem. 2001;276:30399–30406. doi: 10.1074/jbc.M102245200. [PubMed][CrossRef]

265. Ngo J., Matsuyama M., Kim C., Poventud-Fuentes I., Bates A., Siedlak S.L., Lee H., Doughman Y.Q., Watanabe M., Liner A., et al. Bax deficiency extends the survival of Ku70 knockout mice that develop lung and heart diseases. Cell Death Dis. 2015;6:e1706. doi: 10.1038/cddis.2015.11. [PMC free article][PubMed] [CrossRef]

266. Jacquin S., Rincheval V., Mignotte B., Richard S., Humbert M., Mercier O., Londoño-Vallejo A., Fadel E., Eddahibi S. Inactivation of p53 is sufficient to induce development of pulmonary hypertension in rats. PLoS ONE. 2015;10:990 doi: 10.1371/journal.pone.0131940. [PMC free article] [PubMed][CrossRef]

267. Mizuno S., Bogaard H.J., Kraskauskas D., Alhussaini A., Gomez-Arroyo J., Voelkel N.F., Ishizaki T. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011;300:L753–L761. doi: 10.1152/ajplung.00286.2010.[PubMed] [CrossRef]

268. Mouraret N., Marcos E., Abid S., Gary-Bobo G., Saker M., Houssaini A., Dubois-Rande J.-L., Boyer L., Boczkowski J., Derumeaux G., et al. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. Circulation. 2013;127:1664–1676. doi: 10.1161/CIRCULATIONAHA.113.002434. [PMC free article] [PubMed] [CrossRef]

269. Potus F., LeGuen M., Provencher S., Meloche J., Bonnet S. DNA damage at the dawn of micro-RNA pathway impairment in pulmonary arterial hypertension. RNA Dis. 2015;2 doi: 10.14800/rd.810.[CrossRef]

270. Courboulin A., Ranchoux B., Cohen-Kaminsky S., Perros F., Bonnet S. MicroRNA networks in pulmonary arterial hypertension: Share mechanisms with cancer? Curr. Opin. Oncol. 2016;28:72–82. doi: 10.1097/CCO.0000000000000253. [PubMed] [CrossRef]

271. Fang E.F., Scheibye-Knudsen M., Chua K.F., Mattson M.P., Croteau D.L., Bohr V.A. Nuclear DNA damage signalling to mitochondria in ageing. Nat. Rev. Mol. Cell Biol. 2016 doi: 10.1038/nrm.2016.14.[PMC free article] [PubMed] [CrossRef]

272. King A., Selak M.A., Gottlieb E. Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene. 2006;25:4675–4682. doi: 10.1038/sj.onc.1209594.[PubMed] [CrossRef]

273. Boland M.L., Chourasia A.H., Macleod K.F. Mitochondrial dysfunction in cancer. Front. Oncol. 2013;3:292. doi: 10.3389/fonc.2013.00292. [PMC free article] [PubMed] [CrossRef]

274. Sureshbabu A., Bhandari V. Targeting mitochondrial dysfunction in lung diseases: Emphasis on mitophagy. Front. Physiol. 2013;4 doi: 10.3389/fphys.2013.00384. [PMC free article] [PubMed][CrossRef]

275. Tang X., Luo Y.-X., Chen H.-Z., Liu D.-P. Mitochondria, endothelial cell function, and vascular diseases. Front. Physiol. 2014;5 doi: 10.3389/fphys.2014.00175. [PMC free article] [PubMed] [CrossRef]

276. Xu W., Koeck T., Lara A.R., Neumann D., DiFilippo F.P., Koo M., Janocha A.J., Masri F.A., Arroliga A.C., Jennings C., et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc. Natl. Acad. Sci. USA. 2007;104:1342–1347. doi: 10.1073/pnas.0605080104. [PMC free article] [PubMed][CrossRef]

277. Dromparis P., Michelakis E.D. Mitochondria in vascular health and disease. Annu. Rev. Physiol. 2013;75:95–126. doi: 10.1146/annurev-physiol-030212-183804. [PubMed] [CrossRef]

278. Dromparis P., Sutendra G., Michelakis E.D. The role of mitochondria in pulmonary vascular remodeling. J. Mol. Med. 2010;88:1003–1010. doi: 10.1007/s00109-010-0670-x. [PubMed] [CrossRef]

279. Quintero M., Colombo S.L., Godfrey A., Moncada S. Mitochondria as signaling organelles in the vascular endothelium. Proc. Natl. Acad. Sci. USA. 2006;103:5379–5384. doi: 10.1073/pnas.0601026103.[PMC free article] [PubMed] [CrossRef]

280. Kluge M.A., Fetterman J.L., Vita J.A. Mitochondria and Endothelial Function. Circ. Res. 2013;112:1171–1188. doi: 10.1161/CIRCRESAHA.111.300233. [PMC free article] [PubMed] [CrossRef]

281. Vaseva A.V., Moll U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta Bioenerg. 2009;1787:414–420. doi: 10.1016/j.bbabio.2008.10.005. [PMC free article] [PubMed] [CrossRef]

282. Bonnet S., Michelakis E.D., Porter C.J., Andrade-Navarro M.A., Thébaud B., Bonnet S., Haromy A., Harry G., Moudgil R., McMurtry M.S., et al. An abnormal mitochondrial–hypoxia inducible factor-1α–Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats similarities to human pulmonary arterial hypertension. Circulation. 2006;113:2630–2641. doi: 10.1161/CIRCULATIONAHA.105.609008. [PubMed] [CrossRef]

283. Paulin R., Michelakis E.D. The metabolic theory of pulmonary arterial hypertension. Circ. Res. 2014;115:148–164. doi: 10.1161/CIRCRESAHA.115.301130. [PubMed] [CrossRef]

284. Sutendra G., Dromparis P., Wright P., Bonnet S., Haromy A., Hao Z., McMurtry M.S., Michalak M., Vance J.E., Sessa W.C., et al. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci. Transl. Med. 2011;3:88ra55. doi: 10.1126/scitranslmed.3002194.[PMC free article] [PubMed] [CrossRef]

285. Dromparis P., Paulin R., Stenson T.H., Haromy A., Sutendra G., Michelakis E.D. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation. 2013;127:115–125. doi: 10.1161/CIRCULATIONAHA.112.133413. [PubMed] [CrossRef]

286. Cottrill K.A., Chan S.Y. Metabolic dysfunction in pulmonary hypertension: The expanding relevance of the Warburg effect. Eur. J. Clin. Investig. 2013;43:855–865. doi: 10.1111/eci.12104. [PMC free article][PubMed] [CrossRef]

287. Antigny F., Hautefort A., Meloche J., Belacel-Ouari M., Manoury B., Rucker-Martin C., Péchoux C., Potus F., Nadeau V., Tremblay E., et al. Potassium-channel subfamily k-member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation. 2016 doi: 10.1161/CIRCULATIONAHA.115.020951. [PubMed] [CrossRef]

288. Boucherat O., Chabot S., Antigny F., Perros F., Provencher S., Bonnet S. Potassium channels in pulmonary arterial hypertension. Eur. Respir. J. 2015;46:1167–1177. doi: 10.1183/13993003.00798-2015.[PubMed] [CrossRef]

289. McMurtry M.S., Bonnet S., Wu X., Dyck J.R.B., Haromy A., Hashimoto K., Michelakis E.D. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 2004;95:830–840. doi: 10.1161/01.RES.0000145360.16770.9f. [PubMed][CrossRef]

290. Michelakis E.D., McMurtry M.S., Wu X.-C., Dyck J.R.B., Moudgil R., Hopkins T.A., Lopaschuk G.D., Puttagunta L., Waite R., Archer S.L. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002;105:244–250. doi: 10.1161/hc0202.101974. [PubMed] [CrossRef]

291. Diebold I., Hennigs J.K., Miyagawa K., Li C.G., Nickel N.P., Kaschwich M., Cao A., Wang L., Reddy S., Chen P.-I., et al. BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension. Cell Metab. 2015;21:596–608. doi: 10.1016/j.cmet.2015.03.010. [PMC free article] [PubMed] [CrossRef]

292. Fessel J.P., Flynn C.R., Robinson L.J., Penner N.L., Gladson S., Kang C.J., Wasserman D.H., Hemnes A.R., West J.D. Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 2013;49:778–787. doi: 10.1165/rcmb.2012-0463OC. [PMC free article] [PubMed] [CrossRef]

293. Gomez-Arroyo J., Mizuno S., Szczepanek K., van Tassell B., Natarajan R., dos Remedios C.G., Drake J.I., Farkas L., Kraskauskas D., Wijesinghe D.S., et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy due to pulmonary arterial hypertension. Circ. Heart Fail. 2013;6:136–144. doi: 10.1161/CIRCHEARTFAILURE.111.966127. [PMC free article] [PubMed][CrossRef]

294. Sutendra G., Dromparis P., Paulin R., Zervopoulos S., Haromy A., Nagendran J., Michelakis E.D. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J. Mol. Med. 2013;91:1315–1327. doi: 10.1007/s00109-013-1059-4. [PubMed] [CrossRef]

295. Archer S.L., Fang Y.-H., Ryan J.J., Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm. Circ. 2013;3:144–152. doi: 10.4103/2045-8932.109960. [PMC free article] [PubMed] [CrossRef]

296. Cline S.D. Mitochondrial DNA damage and its consequences for mitochondrial gene expression. Biochim. Biophys. Acta. 2012;1819:979–991. doi: 10.1016/j.bbagrm.2012.06.002. [PMC free article][PubMed] [CrossRef]

297. Barja G., Herrero A. Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals. FASEB J. 2000;14:312–318. [PubMed]

298. Yakes F.M., Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. USA. 1997;94:514–519. doi: 10.1073/pnas.94.2.514. [PMC free article] [PubMed] [CrossRef]

299. Tadi S.K., Sebastian R., Dahal S., Babu R.K., Choudhary B., Raghavan S.C. Microhomology-mediated end joining is the principal mediator of double-strand break repair during mitochondrial DNA lesions. Mol. Biol. Cell. 2016;27:223–235. doi: 10.1091/mbc.E15-05-0260. [PMC free article] [PubMed][CrossRef]

300. Grishko V., Solomon M., Wilson G.L., LeDoux S.P., Gillespie M.N. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell phenotypes. Am. J. Physiol. 2001;280:L1300–L1308. [PubMed]

301. López-López L., Nieves-Plaza M., del Castro M.R., Font Y.M., Torres-Ramos C.A., Vilá L.M., Ayala-Peña S. Mitochondrial DNA damage is associated with damage accrual and disease duration in patients with systemic lupus erythematosus. Lupus. 2014;23:1133–1141. doi: 10.1177/0961203314537697.[PMC free article] [PubMed] [CrossRef]

302. Akdogan A., Kilic L., Dogan I., Okutucu S., Er E., Kaya B., Coplu L., Calguneri M., Tokgozoglu L., Ertenli I. Pulmonary hypertension in systemic lupus erythematosus: Pulmonary thromboembolism is the leading cause. J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis. 2013;19:421–425. doi: 10.1097/RHU.0000000000000037. [PubMed] [CrossRef]

303. Asherson R.A. Pulmonary hypertension in systemic lupus erythematosus. J. Rheumatol. 1990;17:414–415. doi: 10.1136/bmj.287.6398.1024-a. [PubMed] [CrossRef]

304. Fetterman J.L., Holbrook M., Westbrook D.G., Brown J.A., Feeley K.P., Bretón-Romero R., Linder E.A., Berk B.D., Weisbrod R.M., Widlansky M.E., et al. Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease. Cardiovasc. Diabetol. 2016;15:53. doi: 10.1186/s12933-016-0372-y. [PMC free article] [PubMed] [CrossRef]

305. Cheng Y., Ren X., Gowda A.S.P., Shan Y., Zhang L., Yuan Y.-S., Patel R., Wu H., Huber-Keener K., Yang J.W., et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis. 2013;4:e731. doi: 10.1038/cddis.2013.254. [PMC free article] [PubMed] [CrossRef]

306. Paulin R., Dromparis P., Sutendra G., Gurtu V., Zervopoulos S., Bowers L., Haromy A., Webster L., Provencher S., Bonnet S., et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab. 2014;20:827–839. doi: 10.1016/j.cmet.2014.08.011. [PubMed] [CrossRef]

307. Szczesny B., Brunyanszki A., Olah G., Mitra S., Szabo C. Opposing roles of mitochondrial and nuclear PARP1 in the regulation of mitochondrial and nuclear DNA integrity: Implications for the regulation of mitochondrial function. Nucleic Acids Res. 2014;42:13161–13173. doi: 10.1093/nar/gku1089. [PMC free article] [PubMed] [CrossRef]

308. Fang E.F., Scheibye-Knudsen M., Brace L.E., Kassahun H., SenGupta T., Nilsen H., Mitchell J.R., Croteau D.L., Bohr V.A. Defective mitophagy in XPA via PARP1 hyperactivation and NAD/+SIRT1 Reduction. Cell. 2014;157:882–896. doi: 10.1016/j.cell.2014.03.026. [PMC free article] [PubMed][CrossRef]

Author Details

1. Mr. Mubashar Tanvir (Virtual University of Pakistan Islamabad)
2. Dr. Saman Asghar Kashmiri (BHU Mandiala, Gujrat)
3. Dr. Maida Ulfat (BHU Channan, Kharian(